{
    "items": "261",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Rally Gains Steam As Powell Signals No More Rate Hikes",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-gains-steam-as-fed-chief-powell-signals-no-more-rate-hikes/",
            "time_published": "20231101T205533",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones futures were little changed hours, along with S&P 500 futures and Nasdaq futures, after Fed chief Jerome Powell signaled the rates will stay on hold into next year. Roku ( ROKU ) and MercadoLibre were among a slew of earnings Wednesday night, with Palantir Technologies ( PLTR ) , Eli ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/stock-Jerome-Powell-03-fed.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.142972,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROKU",
                    "relevance_score": "0.107135",
                    "ticker_sentiment_score": "0.099701",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.107135",
                    "ticker_sentiment_score": "0.012043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.107135",
                    "ticker_sentiment_score": "-0.028084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.107135",
                    "ticker_sentiment_score": "0.01197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.02686",
                    "ticker_sentiment_score": "0.172995",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.263657",
                    "ticker_sentiment_score": "0.132174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "0.056724",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.107135",
                    "ticker_sentiment_score": "0.071799",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.02686",
                    "ticker_sentiment_score": "0.215006",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MCK",
                    "relevance_score": "0.160099",
                    "ticker_sentiment_score": "-0.041109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.133692",
                    "ticker_sentiment_score": "0.008339",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.053689",
                    "ticker_sentiment_score": "-0.079734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.107135",
                    "ticker_sentiment_score": "0.053395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAR",
                    "relevance_score": "0.053689",
                    "ticker_sentiment_score": "-0.079734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "-0.027407",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'AI' Crowned 2023's Word Of The Year, Nudges Out Greedflation, Deinfluencing - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/11/35546444/ai-crowned-2023s-word-of-the-year-nudges-out-greedflation-deinfluencing",
            "time_published": "20231101T184711",
            "authors": [
                "Chris Katje"
            ],
            "summary": "The year 2023 has had its share of themes and innovations, but perhaps none have been as impactful as the rise of artificial intelligence. The choice of \"AI\" as the word of the year by a leading dictionary is unsurprising to many, given its enduring relevance.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/artificial_chart_shutter_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.222015,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.206685",
                    "ticker_sentiment_score": "0.205772",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Earnings Due For These Stealth Weight-Loss Drug Plays",
            "url": "https://www.investors.com/news/mckesson-earnings-stealth-glp-1-weight-loss-drug-play-mckesson-rivals/",
            "time_published": "20231101T172402",
            "authors": [
                "Investor's Business Daily",
                "JED GRAHAM"
            ],
            "summary": "McKesson Earnings Due For Stealth GLP-1 Weight-Loss Drug Play ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/08/Stock-McKesson-03-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.264294,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.190892",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.387674",
                    "ticker_sentiment_score": "0.298988",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MCK",
                    "relevance_score": "0.735092",
                    "ticker_sentiment_score": "0.315229",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.456884",
                    "ticker_sentiment_score": "0.340649",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Exclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - source",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-hires-fujifilm-unit-help-make-wegovy-weight-loss-drug-source-2023-11-01/",
            "time_published": "20231101T171400",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/NCVRREZW2NIHJOO7YHTZGFFXIU.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.152893,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.518708",
                    "ticker_sentiment_score": "0.212648",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "-0.014613",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.182475",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.053828",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Looking for a Growth Stock? 3 Reasons Why Novo Nordisk  ( NVO )  is a Solid Choice",
            "url": "https://www.zacks.com/stock/news/2176658/looking-for-a-growth-stock-3-reasons-why-novo-nordisk-nvo-is-a-solid-choice",
            "time_published": "20231101T164506",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.458713,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.577838",
                    "ticker_sentiment_score": "0.532358",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Should You Buy Novo Nordisk  ( NVO )  Ahead of Earnings?",
            "url": "https://www.zacks.com/stock/news/2176497/should-you-buy-novo-nordisk-nvo-ahead-of-earnings",
            "time_published": "20231101T144300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99237"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.455769,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.893234",
                    "ticker_sentiment_score": "0.590335",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  to Report Q3 Earnings: What's in the Cards?",
            "url": "https://www.zacks.com/stock/news/2176134/novo-nordisk-nvo-to-report-q3-earnings-whats-in-the-cards",
            "time_published": "20231101T113800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999973"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.208895,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LGND",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "0.095082",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACAD",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "0.104658",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BLUE",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "0.027625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.467081",
                    "ticker_sentiment_score": "0.391064",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
            "url": "https://www.zacks.com/stock/news/2176034/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
            "time_published": "20231101T102007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for PPH ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default182.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                }
            ],
            "overall_sentiment_score": 0.16198,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.060139",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.060139",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.042059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.060139",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Novo Nordisk makes its weight-loss drug Wegovy",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/how-novo-nordisk-makes-its-weight-loss-drug-wegovy-2023-11-01/",
            "time_published": "20231101T101700",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "How Novo Nordisk makes its weight-loss drug ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/N75JS65ERZMDBN5TH2CHAFTTIE.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.086363,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APG",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.125808",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.31219",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Supply Is Running Low: Here's Why That Can Be A Problem - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/health-care/23/10/35522328/ozempic-supply-is-running-low-heres-why-that-can-be-a-problem",
            "time_published": "20231031T212345",
            "authors": [
                "Aaron Bry"
            ],
            "summary": "Ozempic, the diabetes drug also used as a so-called \"miracle\" weight-loss drug, has been sweeping through America and is now in limited supply. When used for weight loss, the drug, a GLP-1, helps patients manage their weight.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/31/opzemic.shutterstock_2172980959.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.067732,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.017602",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "-0.011291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.217443",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Never Mind Covid, Investors Want a Pfizer Obesity Pill",
            "url": "https://www.wsj.com/health/pharma/nevermind-covid-investors-want-a-pfizer-obesity-pill-18f6a9e5",
            "time_published": "20231031T163500",
            "authors": [
                "David Wainer"
            ],
            "summary": "The pharmaceutical company's silence on its oral obesity drug worries investors.",
            "banner_image": "https://images.wsj.net/im-877521?width=700&height=466",
            "source": "Wall Street Journal",
            "category_within_source": "Markets",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.294959,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.244118",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.244118",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.633079",
                    "ticker_sentiment_score": "0.390329",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Amgen's stock hit by expectations its obesity pipeline is facing a longer wait",
            "url": "https://www.marketwatch.com/story/amgens-stock-jumps-premarket-after-earnings-beat-and-company-again-raises-guidance-d4015936",
            "time_published": "20231031T155900",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Amgen Inc.'s stock fell 3.3% Tuesday despite an earnings beat and raised guidance. Obesity drugs were to blame.",
            "banner_image": "https://images.mktw.net/im-814193/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.980716"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.104098,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.114297",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "-0.199329",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.288044",
                    "ticker_sentiment_score": "-0.031612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.073546",
                    "ticker_sentiment_score": "0.091052",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.114297",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs",
            "url": "https://www.cnbc.com/2023/10/31/pfizer-pfe-q3-earnings-report-2023.html",
            "time_published": "20231031T110302",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107261572-1687527104868-gettyimages-1246630418-Illustration_Pfizer_Inc.jpeg?v=1687527515&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Earnings",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999162"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.009586,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "-0.12108",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "-0.075254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.065188",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.697809",
                    "ticker_sentiment_score": "0.01151",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies",
            "url": "https://www.zacks.com/stock/news/2175135/zacks-industry-outlook-highlights-dr-reddys-laboratories-amphastar-pharmaceuticals-and-sol-gel-technologies",
            "time_published": "20231031T104300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.17435,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SLGL",
                    "relevance_score": "0.093775",
                    "ticker_sentiment_score": "-0.06028",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.093775",
                    "ticker_sentiment_score": "-0.06028",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.031322",
                    "ticker_sentiment_score": "0.063263",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031322",
                    "ticker_sentiment_score": "0.090919",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Nuveen ESG International Developed Markets Equity ETF  ( NUDM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2175070/is-nuveen-esg-international-developed-markets-equity-etf-nudm-a-strong-etf-right-now",
            "time_published": "20231031T102005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default27.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.231009,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.094988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.094988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.094988",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?",
            "url": "https://www.fool.com/investing/2023/10/31/ozempic-just-shrugged-off-a-challenge-from-viatris/",
            "time_published": "20231031T090500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Viatris now faces a narrower path to commercializing a generic copy of Ozempic.",
            "banner_image": "https://g.foolcdn.com/editorial/images/752405/scientist-looks-at-test-tube.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.048282,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.386306",
                    "ticker_sentiment_score": "0.127534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.613172",
                    "ticker_sentiment_score": "0.050504",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Unusual Options Activity For October 30 - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/10/35499602/novo-nordisk-unusual-options-activity-for-october-30",
            "time_published": "20231030T200048",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Someone with a lot of money to spend has taken a bullish stance on Novo Nordisk NVO. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.20089,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.684999",
                    "ticker_sentiment_score": "0.342164",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will Ozempic Kill Donut Sales? Krispy Kreme Stock Downgraded As Weight Loss Drugs Boom.",
            "url": "https://www.forbes.com/sites/dereksaul/2023/10/30/will-ozempic-kill-donut-sales-krispy-kreme-stock-downgraded-as-weight-loss-drugs-boom/",
            "time_published": "20231030T195751",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Truist cut its outlook Monday for shares of doughnut chain Krispy Kreme, citing the potential impact of weight loss and diabetes drugs like Ozempic, as potentially lower indulgence among Americans weighs broadly on food and beverage stocks.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65400a12042dc92df0919944/0x0.jpg?format=jpg&crop=1553,874,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.034096,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.059374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.034288",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.011108",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.101594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.02319",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.034288",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.031568",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Belgium seizes fake weight-loss drugs containing insulin",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/belgium-seizes-fake-weight-loss-drugs-containing-insulin-2023-10-30/",
            "time_published": "20231030T191800",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/N75JS65ERZMDBN5TH2CHAFTTIE.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.133485,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dow Jones Rises As Apple Climbs Ahead Of Earnings; GM Reportedly Settles With UAW",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-as-apple-climbs-ahead-of-earnings-gm-settles-with-uaw/",
            "time_published": "20231030T150805",
            "authors": [
                "Investor's Business Daily",
                "VIDYA RAMAKRISHNAN"
            ],
            "summary": "Dow Jones Rises As Apple Climbs Ahead Of Earnings. GM ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/stock-WallStreet-06-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999896"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.069208,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.158868",
                    "ticker_sentiment_score": "-0.073442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LSCC",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.142686",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.210731",
                    "ticker_sentiment_score": "0.050436",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMBS",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.158868",
                    "ticker_sentiment_score": "-0.073442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DTST",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "-0.047015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.076727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.158868",
                    "ticker_sentiment_score": "-0.073442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDC",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "-0.052684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.076727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WOLF",
                    "relevance_score": "0.106305",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ON",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.032999",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Generic Drug Stocks to Watch Amid Improving Market Prospects",
            "url": "https://www.zacks.com/commentary/2174308/3-generic-drug-stocks-to-watch-amid-improving-market-prospects",
            "time_published": "20231030T140500",
            "authors": [
                "Sundeep Ganoria"
            ],
            "summary": "The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.169714,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SLGL",
                    "relevance_score": "0.064885",
                    "ticker_sentiment_score": "-0.074367",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.064885",
                    "ticker_sentiment_score": "-0.074367",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032469",
                    "ticker_sentiment_score": "0.096088",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus",
            "url": "https://www.zacks.com/stock/news/2174326/beat-the-market-the-zacks-way-novo-nordisk-lifeway-foods-caseys-in-focus",
            "time_published": "20231030T115200",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/1383.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                }
            ],
            "overall_sentiment_score": 0.17717,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LWAY",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.174446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SKM",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.083224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.107965",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.023136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FCFS",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.213013",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CASY",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.023136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CDRE",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.174446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.060308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.060308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANTX",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.201922",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.1013",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Warren Buffett's $690 Million Secret Portfolio Is Buying 3 Historically Cheap Stocks",
            "url": "https://www.fool.com/investing/2023/10/30/warren-buffett-secret-portfolio-buy-3-cheap-stocks/",
            "time_published": "20231030T090600",
            "authors": [
                "Sean Williams"
            ],
            "summary": "The Oracle of Omaha's under-the-radar investment portfolio is buying shares of three industry-leading businesses.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F752005%2Fbuffett11-tmf.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.196573,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.031322",
                    "ticker_sentiment_score": "0.09646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.216583",
                    "ticker_sentiment_score": "0.136145",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031322",
                    "ticker_sentiment_score": "0.063081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.093775",
                    "ticker_sentiment_score": "0.108779",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.155652",
                    "ticker_sentiment_score": "0.146779",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "European shares rise on healthcare boost, retreating bond yields",
            "url": "https://www.reuters.com/markets/europe/european-shares-rise-healthcare-boost-retreating-bond-yields-2023-10-30/",
            "time_published": "20231030T084600",
            "authors": [
                "Reuters"
            ],
            "summary": "The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, October 27, 2023. REUTERS/Staff Acquire Licensing Rights Oct 30 ( Reuters ) - European shares recovered in early trading on Monday, boosted by healthcare stocks, as bond yields declined with investors ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4GFWP5XBTFLZJIUU42KPZOBAGY.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.1246,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DASTF",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.110581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.110581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.236161",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Clariant delivered strong Catalysts performance and stabilization in Care Chemicals in a continued challenging market environment",
            "url": "https://www.globenewswire.com/news-release/2023/10/30/2768839/0/en/Clariant-delivered-strong-Catalysts-performance-and-stabilization-in-Care-Chemicals-in-a-continued-challenging-market-environment.html",
            "time_published": "20231030T050100",
            "authors": [
                "Clariant International Ltd"
            ],
            "summary": "AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/1eacdab0-4aab-44db-a7fe-16d50f3792c3",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.248486,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.014702",
                    "ticker_sentiment_score": "0.130649",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?",
            "url": "https://www.fool.com/investing/2023/10/29/novo-nordisk-consolidated-grip-on-another-market/",
            "time_published": "20231029T133000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Novo Nordisk is planting the seeds to become a competitor in chronic kidney disease therapies.",
            "banner_image": "https://g.foolcdn.com/editorial/images/752402/two-investors-meet-and-discuss.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.213347,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.302553",
                    "ticker_sentiment_score": "0.303876",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bulls And Bears: Tesla, Chevron, Eli Lilly And Dogecoin Co-founder's 3 Favorite Cryptos",
            "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/10/35465080/benzinga-bulls-and-bears-tesla-chevron-eli-lilly-and-dogecoin-co-founders-3-favorite-cry",
            "time_published": "20231028T124902",
            "authors": [
                "Michael Cohen"
            ],
            "summary": "Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories. This week saw significant declines in major averages, with the Dow, S&P 500, and Nasdaq dropping by 2.1%, 2.5%, and 2.6%, respectively.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/bulls_bears6.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.1194,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.205346",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.205346",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.205346",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "-0.134878",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "0.26513",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.1605",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HES",
                    "relevance_score": "0.303926",
                    "ticker_sentiment_score": "0.381027",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.1605",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "0.273737",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.216949",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:DOGE",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "0.273737",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Medical Stock Was A Welcome Shot For Portfolio Health",
            "url": "https://www.investors.com/research/swing-trading/nvo-stock-ended-up-being-healthy-for-swing-trading-portfolios/",
            "time_published": "20231027T202300",
            "authors": [
                "JUSTIN NIELSEN",
                "Investor's Business Daily"
            ],
            "summary": "NVO Stock Ended Up Being Healthy For Swing Trading Portfolios Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/wSWING103023.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.226303,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.628066",
                    "ticker_sentiment_score": "0.356818",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/health-care/23/10/35469218/is-ozempic-killing-liposuction-a-stock-that-could-get-hit-hard-from-new-weight-loss-drugs",
            "time_published": "20231027T191555",
            "authors": [
                "Aaron Bry"
            ],
            "summary": "Ozempic, Novo Nordisk's NVO diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such as liposuction and bariatric surgeries. Some companies are already seeing the impact of widespread Ozempic use.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/weightloss.shutterstock_2270507665.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.062611,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.316846",
                    "ticker_sentiment_score": "-0.116065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.316846",
                    "ticker_sentiment_score": "-0.073174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.316846",
                    "ticker_sentiment_score": "-0.31328",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM",
            "url": "https://www.benzinga.com/pressreleases/23/10/g35471986/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-outset-medical-",
            "time_published": "20231027T190453",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Oct. 27, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ( \"Outset\" or the \"Company\" ) OM. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.036418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.043502",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/non-alcoholic-steatohepatitis-market-to-grow-by-usd-11-22-billion--from-2022-to-2027--north-america-to-account-for-51-of-market-growth--technavio-301969658.html",
            "time_published": "20231027T183000",
            "authors": [],
            "summary": "Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.239625,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ENZ",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GNFT",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVA",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SEMHF",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ICPT",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "No Proven Link Between Weight Loss Drugs And Thyroid Cancer, EU Says",
            "url": "https://www.forbes.com/sites/tylerroush/2023/10/27/no-proven-link-between-weight-loss-drugs-and-thyroid-cancer-eu-says/",
            "time_published": "20231027T134701",
            "authors": [
                "Ty Roush"
            ],
            "summary": "There is no evidence to suggest weight loss and diabetes drugs like Ozempic or Wegovy cause thyroid cancer, a European Union agency said Friday, easing fears after a previous study suggested using similar drugs resulted in an increased risk of all thyroid cancers for people with type two diabetes.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/653bbebc065d2afe7c03484f/0x0.jpg?format=jpg&crop=5190,2921,x3,y111,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.224727,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.082393",
                    "ticker_sentiment_score": "-0.082582",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "-0.10737",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-Loss Beating Continues For Devices Makers; Why It's Overdone",
            "url": "https://www.investors.com/news/technology/weight-loss-drugs-spook-medical-device-stocks-an-overreaction/",
            "time_published": "20231027T130000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/IT2c103023-300x171.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997405"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.093424,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "INSP",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "-0.017925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZBH",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.125221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.017458",
                    "ticker_sentiment_score": "-0.108231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.087122",
                    "ticker_sentiment_score": "0.080517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMD",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.125221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.23697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.087122",
                    "ticker_sentiment_score": "0.002112",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EW",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.23697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.017458",
                    "ticker_sentiment_score": "0.047327",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.069748",
                    "ticker_sentiment_score": "0.111489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.034907",
                    "ticker_sentiment_score": "0.099119",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLNO",
                    "relevance_score": "0.017458",
                    "ticker_sentiment_score": "0.014131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.05234",
                    "ticker_sentiment_score": "0.026937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.121738",
                    "ticker_sentiment_score": "0.072049",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs Like Wegovy Would Not Impact Business - Healthcare Companies Tell Investors - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35461521/weight-loss-drugs-like-wegovy-would-not-impact-business-healthcare-companies-tell-investors",
            "time_published": "20231027T115156",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO investors and analysts eagerly await the company's third-quarter results, hoping for clarity on when supply limitations for its weight-loss drug, Wegovy, in the U.S. will be resolved.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.038857,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "-0.435366",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.395012",
                    "ticker_sentiment_score": "0.506218",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "-0.01004",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk A/S and Lowe's",
            "url": "https://www.zacks.com/stock/news/2173468/the-zacks-analyst-blog-highlights-microsoft-novo-nordisk-as-and-lowes",
            "time_published": "20231027T105000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Microsoft, Novo Nordisk A/S and Lowe's are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.2469,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.017927",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.344712",
                    "ticker_sentiment_score": "0.196638",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.019439",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo investors seek clarity on Wegovy weight-loss drug shortages",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-investors-seek-clarity-wegovy-weight-loss-drug-shortages-2023-10-27/",
            "time_published": "20231027T055924",
            "authors": [
                "Maggie Fick",
                "Jacob Gronholt-Pedersen"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/0c0cce11-2168-4aa1-bb10-ec93b237ee28.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.147585,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.114409",
                    "ticker_sentiment_score": "0.025032",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.057352",
                    "ticker_sentiment_score": "0.081032",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.057352",
                    "ticker_sentiment_score": "0.176993",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Analysis: Healthcare companies counter investor worries over Wegovy effect",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/healthcare-companies-counter-investor-worries-over-wegovy-effect-2023-10-27/",
            "time_published": "20231027T050020",
            "authors": [
                "Manas Mishra",
                "David Gaffen"
            ],
            "summary": "A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/64c98ae2-82dc-4c80-b81f-dc010b8de5de.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.040704,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "RMD",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.003987",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.018908",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.052759",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.016001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.124991",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "-0.129072",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "British health agency warns of fake Ozempic pens linked to hospitalizations",
            "url": "https://www.cnn.com/2023/10/26/health/british-health-agency-warns-of-fake-ozempic-pens-linked-to-hospitalizations/index.html",
            "time_published": "20231026T204800",
            "authors": [
                "Amanda Musa"
            ],
            "summary": "British regulators warn of fake Ozempic pens linked to hospitalizations ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231005145408-ozempic-injection-drug-restricted.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.150705,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.220141",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.290607",
                    "ticker_sentiment_score": "0.017239",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results - Coca-Cola  ( NYSE:KO ) , Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , PepsiCo  ( NASDAQ:PEP ) ",
            "url": "https://www.benzinga.com/news/23/10/35449786/weight-loss-drugs-wegovy-ozempic-gain-traction-with-millennials-high-earners-new-survey-results",
            "time_published": "20231026T193958",
            "authors": [
                "Chris Katje"
            ],
            "summary": "Prescription weight loss drugs Ozempic, Wegovy and Mounjaro have dominated headlines in 2023 with increased interest and the impact being discussed by food and drink companies. Here's a look at the consumer segments that might be driving the enthusiasm and demand for these GLP-1 drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/weight_loss_shutter.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.075909,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.158745",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "-0.073057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "-0.073057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.225997",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "-0.109201",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Q3 Earnings Season Scorecard - Earnings Growth Turns Positive",
            "url": "https://www.zacks.com/research-daily/2172539/q3-earnings-season-scorecard---earnings-growth-turns-positive",
            "time_published": "20231026T183600",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "Today's Research Daily features real-time scorecard of the Q3 earnings season in addition to Microsoft (MSFT), Novo Nordisk (NVO), Lowe's (LOW) and others.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default156.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999954"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.247379,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.233693",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.191907",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.019047",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "NVO: 3 Pharma Stocks With Market Impact to Consider Buying",
            "url": "https://stocknews.com/news/nvo-rdy-amrx-3-pharma-stocks-with-market-impact-to-consider-buying/",
            "time_published": "20231026T175544",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "The pharmaceutical sector is well-positioned for growth, thanks to growing healthcare expenses, an increasing global elderly population, and a growing prevalence of lifestyle-related diseases.",
            "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_517925923-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999986"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.246098,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MCO",
                    "relevance_score": "0.054483",
                    "ticker_sentiment_score": "-0.114008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMRX",
                    "relevance_score": "0.162437",
                    "ticker_sentiment_score": "0.163533",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.201593",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.189034",
                    "ticker_sentiment_score": "0.160917",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Looking At Novo Nordisk's Recent Unusual Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/10/35442295/looking-at-novo-nordisks-recent-unusual-options-activity",
            "time_published": "20231026T144721",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 12 strange trades. If we consider the specifics of each trade, it is accurate to state that 16% of the investors opened trades with bullish ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.141937,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.696319",
                    "ticker_sentiment_score": "0.056816",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "InnovationRx: Ransomware Attacks On U.S. Health Systems Have Cost The Economy Nearly $80 Billion",
            "url": "https://www.forbes.com/sites/alexknapp/2023/10/25/innovationrx-ransomware-attacks-on-us-health-systems-have-cost-the-economy-nearly-8-billion/",
            "time_published": "20231026T004247",
            "authors": [
                "Alex Knapp"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6539b5a9b1998d930ede083e/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.031463,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "-0.055926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTXR",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.107688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "-0.114687",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.059975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "-0.292031",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CNC",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.120688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TENK",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.107688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INSM",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "-0.068726",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BFLY",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.059975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:PAY",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.107688",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Stock Moves -0.09%: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2172041/novo-nordisk-nvo-stock-moves--009-what-you-should-know",
            "time_published": "20231025T214518",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Novo Nordisk (NVO) closed at $97.43, marking a -0.09% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.155372,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.507932",
                    "ticker_sentiment_score": "0.263476",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic craze drives big flows into pharmaceutical, Danish funds",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/ozempic-craze-drives-big-flows-into-pharmaceutical-danish-funds-2023-10-25/",
            "time_published": "20231025T155200",
            "authors": [
                "Bansari Kamdar"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration//File Photo Acquire Licensing Rights",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/36cd72fb-82f8-4f2c-848e-6faa6950a36e.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.714479"
                }
            ],
            "overall_sentiment_score": 0.014277,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "-0.128022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.040749",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.",
            "url": "https://www.fool.com/investing/2023/10/25/demand-for-ozempic-and-wegovy-is-through-the-roof/",
            "time_published": "20231025T114400",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Employers could help bolster demand for weight-loss treatments.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.223001,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.070517",
                    "ticker_sentiment_score": "0.102549",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.464393",
                    "ticker_sentiment_score": "0.357148",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": " ( NVO )  - Analyzing Novo Nordisk's Short Interest - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/short-sellers/23/10/35398092/nvo-analyzing-novo-nordisks-short-interest",
            "time_published": "20231024T154528",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk's NVO short percent of float has risen 45.45% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 0.16% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.267332,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.155473",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "JNJ: Should You Invest in Johnson & Johnson  ( JNJ )  Following Q3 Results",
            "url": "https://stocknews.com/news/jnj-nvs-abbv-nvo-should-you-invest-in-johnson-johnson-jnj-following-q3/",
            "time_published": "20231024T144418",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "JNJ: Should You Invest in Johnson & Johnson ( JNJ ) Following Q3 ... ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2020/09/jnj-mmm-dg.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999975"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.217713,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.083687",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.083687",
                    "ticker_sentiment_score": "0.067449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.083687",
                    "ticker_sentiment_score": "0.067449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083687",
                    "ticker_sentiment_score": "0.067449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.628234",
                    "ticker_sentiment_score": "0.331411",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "1 Green Flag and 1 Red Flag for Novo Nordisk",
            "url": "https://www.fool.com/investing/2023/10/24/1-green-flag-and-1-red-flag-for-novo-nordisk/",
            "time_published": "20231024T130000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Even this high-flying company has its detractors.",
            "banner_image": "https://media.ycharts.com/charts/b46c157ac2d9cbf7500dba088cc52a49.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.221733,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.513606",
                    "ticker_sentiment_score": "0.31345",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Coke, others, may be spared, as a $100 billion opportunity in weight loss drugs unfolds says JPMorgan",
            "url": "https://www.marketwatch.com/story/the-weight-loss-drugs-are-coming-for-these-companies-but-heres-why-coke-others-may-be-spared-says-jpmorgan-c6c24538",
            "time_published": "20231024T104200",
            "authors": [
                "Barbara Kollmeyer"
            ],
            "summary": "JPMorgan says the weight-loss drug industry is now a \"$100 billion plus opportunity.\" Coke is one of the stocks they say is likely to get hit less hard.",
            "banner_image": "https://images.mktw.net/im-874075?width=700&height=763",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.129162,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KO",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.038342",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.067688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.116945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.019258",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "-0.045214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.095915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HPNN",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.243126",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TXN",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.116945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVTR",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.067688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.140662",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DHR",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.067688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.182706",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.243126",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KDP",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.142685",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.116945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.083395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RGEN",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.067688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "-0.10898",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.211781",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SFM",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.142685",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.140662",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.211781",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "-0.10898",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data",
            "url": "https://www.cnbc.com/2023/10/24/signos-raised-20-million-to-tackle-weight-loss-with-cgms-and-data.html",
            "time_published": "20231024T100001",
            "authors": [
                "Ashley Capoot"
            ],
            "summary": "Signos, a Silicon Valley startup that's trying to help consumers lose weight, raised $20 million in a funding round led by Cheyenne Ventures and GV.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107315308-16970398441697039842-31555766578-1080pnbcnews.jpg?v=1697040673&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.165461,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.039944",
                    "ticker_sentiment_score": "0.109745",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.039944",
                    "ticker_sentiment_score": "0.135374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.158781",
                    "ticker_sentiment_score": "0.147437",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.039944",
                    "ticker_sentiment_score": "-0.217865",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.039944",
                    "ticker_sentiment_score": "0.239868",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Historically Cheap Dow Dividend Kings That Are Ripe for the Picking",
            "url": "https://www.fool.com/investing/2023/10/24/2-cheap-dow-dividend-kings-are-ripe-for-picking/",
            "time_published": "20231024T092100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "These inexpensive Dow components have achieved royalty status among income stocks -- more than 60 consecutive years of dividend increases.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F751877%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.228638,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.038223",
                    "ticker_sentiment_score": "0.004947",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TWOHD",
                    "relevance_score": "0.038223",
                    "ticker_sentiment_score": "0.270018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.333757",
                    "ticker_sentiment_score": "0.353798",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.038223",
                    "ticker_sentiment_score": "0.200047",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076358",
                    "ticker_sentiment_score": "-0.041088",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.298567",
                    "ticker_sentiment_score": "0.116827",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.038223",
                    "ticker_sentiment_score": "0.201042",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.038223",
                    "ticker_sentiment_score": "0.004947",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Advances While Market Declines: Some Information for Investors",
            "url": "https://www.zacks.com/stock/news/2170462/novo-nordisk-nvo-advances-while-market-declines-some-information-for-investors",
            "time_published": "20231023T215019",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The latest trading day saw Novo Nordisk (NVO) settling at $97.12, representing a +0.86% change from its previous close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default141.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                }
            ],
            "overall_sentiment_score": 0.110865,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.566715",
                    "ticker_sentiment_score": "0.181964",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond - A look at the numbers",
            "url": "https://www.cnbc.com/2023/10/23/wall-street-hikes-forecasts-for-anti-obesity-drug-sales-to-100-billion.html",
            "time_published": "20231023T194724",
            "authors": [
                "Christina Cheddar Berk"
            ],
            "summary": "Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here's why.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107231937-16825975612023-03-29t000000z_583469951_rc2w30aoohoj_rtrmadp_0_usa-health.jpeg?v=1698090444&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Investing",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.031081,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.009021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "-0.286804",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.066287",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.190667",
                    "ticker_sentiment_score": "0.142123",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Maker Novo Nordisk Has a Weight Problem",
            "url": "https://www.wsj.com/finance/ozempic-maker-novo-nordisk-has-a-weight-problem-f84feed5",
            "time_published": "20231023T153900",
            "authors": [
                "Stephen Wilmot"
            ],
            "summary": "What happens when one company accounts for more than half of a stock index?",
            "banner_image": "https://images.wsj.net/im-871855?width=700&height=467",
            "source": "Wall Street Journal",
            "category_within_source": "Markets",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.187201,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.368514",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.615462",
                    "ticker_sentiment_score": "0.381329",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Maker Novo Nordisk Has a Weight Problem",
            "url": "https://www.wsj.com/finance/ozempic-maker-novo-nordisk-has-a-weight-problem-f84feed5",
            "time_published": "20231023T153900",
            "authors": [
                "Stephen Wilmot"
            ],
            "summary": "What happens when one company accounts for more than half of a stock index?",
            "banner_image": "https://images.wsj.net/im-871855/social",
            "source": "Wall Street Journal",
            "category_within_source": "Markets",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.258637,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.431215",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.431215",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/10/23/2764749/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231023T125100",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 23 October 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Fake Ozempic Pens Circulating In Europe, Watchdogs Warn",
            "url": "https://www.barrons.com/news/fake-ozempic-pens-circulating-in-europe-watchdogs-warn-ded16113",
            "time_published": "20231023T114300",
            "authors": [
                "AFP - Agence France Presse"
            ],
            "summary": "Fake injection pens of Ozempic, a hugely popular diabetes drug that went viral on social media as a way to lose weight, are circulating in Europe, drug authorities have warned. Ozempic, which involves a once-weekly injection from a pre-filled pen, was originally developed to treat type 2 diabetes.",
            "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP8003435139896138958801083518862648389411---1.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.142108,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.068966",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Take the Zacks Approach to Beat the Market: Novo Nordisk, Amgen, Fabrinet in Focus",
            "url": "https://www.zacks.com/stock/news/2170088/take-the-zacks-approach-to-beat-the-market-novo-nordisk-amgen-fabrinet-in-focus",
            "time_published": "20231023T092300",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998682"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                }
            ],
            "overall_sentiment_score": 0.14354,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LULU",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.023094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.107081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOH",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.083127",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FN",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.212679",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KRP",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.137099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.061217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.061217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FICO",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.101176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ICFI",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.023094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MMYT",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.137099",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Analysis: Anti-obesity drugs can be boost for food makers, investors say",
            "url": "https://www.reuters.com/business/retail-consumer/anti-obesity-drugs-can-be-boost-food-makers-investors-say-2023-10-23/",
            "time_published": "20231023T001109",
            "authors": [
                "David Randall",
                "Richa Naidu"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/R4C7KDQ6GRIIBCLQYAFYEYDDMA.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.1248,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HESG",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "-0.022026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARCO",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.061988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "-0.254072",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.061988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AIVAF",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "-0.103997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.18601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "-0.254072",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.064392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSN",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.061988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.058988",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Hidden Gems: 3 Stealthy AI Stocks Quietly Conquering the 2023 Market",
            "url": "https://www.fool.com/investing/2023/10/22/hidden-gems-3-stealthy-ai-stocks/",
            "time_published": "20231022T111900",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Twilio, UiPath, and Ginkgo Bioworks are all massively underrated opportunities in artificial intelligence.",
            "banner_image": "https://media.ycharts.com/charts/90cfe1abccd1b8a1ff0bde19890a81ca.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999612"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.15061,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.066691",
                    "ticker_sentiment_score": "0.101642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PATH",
                    "relevance_score": "0.26217",
                    "ticker_sentiment_score": "0.145241",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "0.072452",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.137295",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APG",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.035546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.137295",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.035546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.035546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.137295",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Unstoppable Stocks to Buy Sooner Rather Than Later",
            "url": "https://www.fool.com/investing/2023/10/22/3-unstoppable-stocks-to-buy-sooner-rather-than-lat/",
            "time_published": "20231022T105500",
            "authors": [
                "and Prosper Junior Bakiny",
                "David Jagielski",
                "Keith Speights"
            ],
            "summary": "Now is the time to invest in these great stocks.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.172773,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.287441",
                    "ticker_sentiment_score": "0.100872",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.166743",
                    "ticker_sentiment_score": "0.014889",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.326283",
                    "ticker_sentiment_score": "0.046633",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cathie Wood Just Doubled Down on This Biotech Stock. Should You Follow Her Lead?",
            "url": "https://www.fool.com/investing/2023/10/21/cathie-wood-just-doubled-down-on-this-biotech-stoc/",
            "time_published": "20231021T104500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Cathie Wood has bought over 5 million shares in Ginkgo Bioworks so far this month.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750320%2Fgettyimages-1441663123.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997405"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.15817,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.125551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.419575",
                    "ticker_sentiment_score": "0.200977",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.080055",
                    "ticker_sentiment_score": "0.110537",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.080055",
                    "ticker_sentiment_score": "0.131308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSUMF",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.125551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.125203",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Stock-Split Stock Is Beating Both Apple and Microsoft in 2023 -- With No Artificial Intelligence  ( AI )  Tailwind at All",
            "url": "https://www.fool.com/investing/2023/10/21/stock-split-beating-apple-microsoft-ai/",
            "time_published": "20231021T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "This big pharma stock has been a big winner, thanks to two blockbuster drugs.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.145391,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.134534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.134534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.614836",
                    "ticker_sentiment_score": "0.229189",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly, Novo Nordisk test popular weight loss-related drugs on children",
            "url": "https://www.foxbusiness.com/lifestyle/eli-lilly-novo-nordisk-test-popular-weight-loss-related-drugs-children",
            "time_published": "20231020T220753",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "Drugmakers Eli Lilly and Novo Nordisk are testing some of their most popular diabetes and weight loss drugs on patients as young as 6. Indiana-based Lilly is planning to test tirzepatide, sold under the brand name Mounjaro, on children and teenagers with Type 2 diabetes who are overweight or ...",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/425a9dfa-208f-4282-9618-d56e78768726/f911a033-5638-447f-914e-e84b1d8bb5f0/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.113234,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.275867",
                    "ticker_sentiment_score": "0.091749",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "War Clouds Call For Bulletproof Investing: With The Mideast War Threatening To Spread, Another Way To Limit Your Risk - ASML Holding  ( NASDAQ:ASML ) , Fair Isaac  ( NYSE:FICO ) ",
            "url": "https://www.benzinga.com/trading-ideas/23/10/35354214/war-clouds-call-for-bulletproof-investing-with-the-mideast-war-threatening-to-spread-another-way-to",
            "time_published": "20231020T162258",
            "authors": [
                "David Pinsen"
            ],
            "summary": "In our post yesterday ( The Guns Of October ) we wrote about the risk of the current Mideast war spreading and mentioned one way to limit your risk in light of that: hedging the stocks or ETFs you own. The Guns Of October: Preventing World War III$SPYhttps://t.co/9GR6qk7ssZ",
            "banner_image": "data:image/png;base64,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?optimize=medium&dpr=2&auto=webp&width=1920",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.004789,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSIT",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WYNN",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FICO",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.003714",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "$1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/10/35353636/1000-invested-in-novo-nordisk-5-years-ago-would-be-worth-this-much-today",
            "time_published": "20231020T160047",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 5 years by 26.08% on an annualized basis producing an average annual return of 35.15%. Currently, Novo Nordisk has a market capitalization of $435.96 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Medical device makers see limited hit from weight-loss drugs",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/medical-device-makers-see-limited-hit-weight-loss-drugs-2023-10-20/",
            "time_published": "20231020T141800",
            "authors": [
                "Reuters"
            ],
            "summary": "[1/2] Boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/V6WKJ3BLKRML3BRCVWOIWT5H3M.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.011811,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.005137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.156461",
                    "ticker_sentiment_score": "-0.029172",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "UK online pharmacy Rightangled still selling diabetes drug Ozempic despite govt order",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/uk-online-pharmacy-rightangled-still-selling-diabetes-drug-ozempic-despite-govt-2023-10-20/",
            "time_published": "20231020T141000",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4KVIGMQPHBOT3EMJQOHBSR62UA.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.028198,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.111794",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View",
            "url": "https://www.zacks.com/stock/news/2169495/pharma-stock-roundup-jnj-posts-upbeat-q3-earnings-pfe-nvo-revise-2023-view",
            "time_published": "20231020T130200",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.994953"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.102884,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.064362",
                    "ticker_sentiment_score": "-0.153214",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.128306",
                    "ticker_sentiment_score": "-0.016733",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.128306",
                    "ticker_sentiment_score": "-0.016733",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.032207",
                    "ticker_sentiment_score": "-0.277037",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.222546",
                    "ticker_sentiment_score": "0.12752",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.253316",
                    "ticker_sentiment_score": "-0.128908",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-diabetes-drug-trial-kids-young-6-years-bloomberg-2023-10-20/",
            "time_published": "20231020T103400",
            "authors": [
                "Reuters"
            ],
            "summary": "A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/FWCSD7OYQBIAXAIQE75TKOQBZM.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.041908,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.200688",
                    "ticker_sentiment_score": "-0.096014",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Focus: -Demand for weight-loss drugs fuels global rise in counterfeits",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/demand-weight-loss-drugs-fuels-global-rise-counterfeits-2023-10-20/",
            "time_published": "20231020T100500",
            "authors": [
                "Patrick Wingrove",
                "Maggie Fick"
            ],
            "summary": "[1/2] Boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RZUU2AEA3ROCVG6D6KFWGWZ5AY.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.016798,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.08375",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pressure Mounts As Yields Flirt With 5%; Fear Gauge Offers Hope",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-pressure-mounts-as-yields-flirt-with-5-tesla-dives-this-market-gauge-offers-hope/",
            "time_published": "20231019T203200",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Pressure Mounts As Yields Flirt With 5%. Fear Gauge Offers Hope Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/01/FAB-fear-020518-shutterstock.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.053454,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.236588",
                    "ticker_sentiment_score": "0.089875",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.159043",
                    "ticker_sentiment_score": "-0.05506",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.210961",
                    "ticker_sentiment_score": "0.005183",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05333",
                    "ticker_sentiment_score": "-0.271887",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "UNP",
                    "relevance_score": "0.05333",
                    "ticker_sentiment_score": "-0.159029",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.185103",
                    "ticker_sentiment_score": "0.021017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.05333",
                    "ticker_sentiment_score": "-0.271887",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SLB",
                    "relevance_score": "0.106423",
                    "ticker_sentiment_score": "0.112494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.106423",
                    "ticker_sentiment_score": "-0.230299",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.106423",
                    "ticker_sentiment_score": "0.010019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM",
            "url": "https://www.benzinga.com/pressreleases/23/10/g35338093/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-outset-medical-",
            "time_published": "20231019T191958",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ( \"Outset\" or the \"Company\" ) OM. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.036418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.043502",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Anti-obesity drugs are an investable \"fountain of youth\" for baby boomers",
            "url": "https://www.investorideas.com/news/2023/biotech/10191RichardMills-Anti-Obesity-Drugs.asp",
            "time_published": "20231019T182325",
            "authors": [],
            "summary": "Anti-obesity drugs are an investable \"fountain of youth\" for baby ... ...",
            "banner_image": "https://aheadoftheherd.com/app/uploads/2023/10/ozempic-effect.png",
            "source": "Investor Ideas",
            "category_within_source": "n/a",
            "source_domain": "www.investorideas.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.041022,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MO",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "-0.079627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.055477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.026815",
                    "ticker_sentiment_score": "0.098503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.048388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.048388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "-0.034385",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.048388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.055477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.00788",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STZ",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.098089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.055477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.013409",
                    "ticker_sentiment_score": "0.095434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.026815",
                    "ticker_sentiment_score": "0.036404",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.026815",
                    "ticker_sentiment_score": "-0.027861",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Unusual Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/10/35336753/novo-nordisk-unusual-options-activity",
            "time_published": "20231019T180152",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 13 strange trades. If we consider the specifics of each trade, it is accurate to state that 15% of the investors opened trades with bullish ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.155935,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056612",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-hires-cordenpharma-make-diabetes-drug-mounjaros-active-ingredient-source-2023-10-19/",
            "time_published": "20231019T175800",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RZUU2AEA3ROCVG6D6KFWGWZ5AY.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.073652,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "-0.039689",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "GoodRx to offer Sanofi's insulin injection for only $35",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/goodrx-offer-sanofis-insulin-injection-only-35-2023-10-19/",
            "time_published": "20231019T165500",
            "authors": [
                "Reuters"
            ],
            "summary": "GoodRx to offer Sanofi's insulin injection for only ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QVC3ZGLBCVPPPLCGKX762XHH7Q.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.147867,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GDRX",
                    "relevance_score": "0.334008",
                    "ticker_sentiment_score": "-0.079188",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "-0.088147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.612033",
                    "ticker_sentiment_score": "-0.174268",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Sanofi to offer insulin product for $35 to all Americans through GoodRx",
            "url": "https://www.cnbc.com/2023/10/19/sanofi-to-offer-insulin-for-35-to-americans-through-goodrx.html",
            "time_published": "20231019T143102",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The effort comes after Sanofi, Eli Lilly and Novo Nordisk announced sweeping insulin price cuts earlier this year.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107320030-1697723841561-gettyimages-1135806215-INSULIN_DRUG_PRICING.jpeg?v=1697725862&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.004831,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.059849",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GDRX",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.074605",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHR",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.123231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.052482",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "-0.054225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.059849",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Anti-Obesity Drugs Are On The Come Up In A $44 Billion Market By 2030",
            "url": "https://www.forbes.com/sites/korihale/2023/10/19/anti-obesity-drugs-are-on-the-come-up-in-a-44-billion-market-by-2030/",
            "time_published": "20231019T133118",
            "authors": [
                "Kori Hale"
            ],
            "summary": "Particularly, the Black community bears the brunt of this health crisis as 49% of adults in this demographic qualify as obese.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651c0d328c22c4372b6e3691/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "Money",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.014639,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.113149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "-0.03252",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Market-Beating Stock to Buy Near Its 52-Week High",
            "url": "https://www.fool.com/investing/2023/10/19/1-market-beating-stock-to-buy-near-52-week-high/",
            "time_published": "20231019T133000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "This stock has been firing on all cylinders -- and it isn't about to stop.",
            "banner_image": "https://media.ycharts.com/charts/a1505ef731280b97dff5e5bf069c8c9a.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.282021,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.268",
                    "ticker_sentiment_score": "0.214712",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACCD",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "-0.063291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.011564",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "4 Ways to Grow $100,000 Into $1 Million for Retirement",
            "url": "https://www.fool.com/investing/2023/10/19/4-ways-to-grow-100000-into-1-million-for-retiremen/",
            "time_published": "20231019T131300",
            "authors": [
                "Jim Halley"
            ],
            "summary": "Investing for big-time growth doesn't have to be risky.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999966"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.206499,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.122393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.077343",
                    "ticker_sentiment_score": "0.050792",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.077343",
                    "ticker_sentiment_score": "0.055791",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.097293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "O",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.0852",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Thing You'd Better Know Before You Invest in the Stocks Behind Ozempic and Mounjaro",
            "url": "https://www.fool.com/investing/2023/10/19/1-thing-you-better-know-before-invest-in-ozempic/",
            "time_published": "20231019T130000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly and Novo Nordisk are both battling demand issues for flagship treatments.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750321%2Fgettyimages-1404901940.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.215497,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.52706",
                    "ticker_sentiment_score": "0.344682",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.038162",
                    "ticker_sentiment_score": "0.041449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.58401",
                    "ticker_sentiment_score": "0.334632",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Beware Of Fake Novo Nordisk's Ozempic - European, UK Regulators Warn About Fake Prefilled Pens - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35323980/beware-of-fake-novo-nordisks-ozempic-european-uk-regulators-warn-about-fake-prefilled-pens",
            "time_published": "20231019T125724",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The European Medicines Agency warned about pre-filled pens falsely labeled as Novo Nordisk A/S's NVO popular diabetes drug Ozempic at wholesalers in the European Union and the U.K. The latest reports of falsification come in the wake of an increase in demand for Ozempic, which has also led to a ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/19/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.152924,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.524949",
                    "ticker_sentiment_score": "0.288593",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "GE HealthCare teams up with Novo Nordisk to treat diabetes without drugs",
            "url": "https://www.marketwatch.com/story/ge-healthcare-teams-up-with-novo-nordisk-to-treat-diabetes-without-drugs-7b679c3e",
            "time_published": "20231019T123600",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "New ultrasound technology has potential to regulate metabolic function, early-stage clinical research shows ...",
            "banner_image": "https://images.mktw.net/im-866288/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.138482,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.151953",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Corporate America weighs risks of the Ozempic effect",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/corporate-america-weighs-risks-ozempic-effect-2023-10-19/",
            "time_published": "20231019T112800",
            "authors": [
                "Reuters"
            ],
            "summary": "Boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QBKENUA4NBKF7OENKFKMX6MUYM.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.117802,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.182216",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.085254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.034637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.131114",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "-0.049676",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.034637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "-0.024285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.037046",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.270432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nestlé Is Developing Products To Accompany Weight-Loss Drugs Like Ozempic- Amid Fears They'll Eat Into Food Sales",
            "url": "https://www.forbes.com/sites/roberthart/2023/10/19/nestl-is-developing-products-to-accompany-weight-loss-drugs-like-ozempic--amid-fears-theyll-eat-into-food-sales/",
            "time_published": "20231019T100024",
            "authors": [
                "Robert Hart"
            ],
            "summary": "Nestlé's chief executive said the appetite-killing drugs hadn't cut into food sales yet-but created an opportunity for supplements and products to help people keep weight off.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6530fe0be669377c1c2cad55/0x0.jpg?format=jpg&crop=3838,2157,x0,y200,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "Business",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.117009,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "0.03904",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083541",
                    "ticker_sentiment_score": "0.082114",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "European regulators warn of fake Ozempic pens found at wholesalers in EU, UK amid shortage",
            "url": "https://www.cnn.com/2023/10/18/health/fake-ozempic-european-regulators/index.html",
            "time_published": "20231018T170900",
            "authors": [
                "Meg Tirrell"
            ],
            "summary": "Fake versions of the popular diabetes medicine Ozempic have been found at wholesalers in the European Union and United Kingdom, the European Medicines Agency warned Wednesday, prompting an alert to patients to check their medicines carefully.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230620162507-novo-nordisk-lawsuits.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.116444,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.095899",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.370143",
                    "ticker_sentiment_score": "-0.148992",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "People of African ancestry are poorly represented in genetic studies. A new effort would change that",
            "url": "https://apnews.com/article/genetics-african-ancestry-black-americans-hbcu-2b19d22d04392ff31871c008e7133e4f",
            "time_published": "20231018T145200",
            "authors": [
                "LAURA UNGAR"
            ],
            "summary": "Scientists are setting out to collect genetic material from 500,000 people of African ancestry to create what they believe will be the world's largest database of genomic information from the population.",
            "banner_image": "https://dims.apnews.com/dims4/default/acf2e7b/2147483647/strip/true/crop/5204x3466+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F5e%2F2a%2F125ae6a43bc9adfbdafe96a51f2f%2F8c70064dccd342b08ed8358c698746df",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.147593,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HESG",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.084481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HHH",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.168255",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.074409",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.074409",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "European regulator warns EU, UK on fake Ozempic pens",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-medicines-regulator-warns-eu-uk-fake-ozempic-pens-2023-10-18/",
            "time_published": "20231018T143600",
            "authors": [
                "Reuters"
            ],
            "summary": "EU medicines regulator warns EU, UK on fake Ozempic pens ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RZUU2AEA3ROCVG6D6KFWGWZ5AY.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.272039,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Management Market size to grow by USD 85.5 billion from 2022-2027| Amway Corp., Astellas Pharma Inc ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/weight-management-market-size-to-grow-by-usd-85-5-billion-from-2022-2027-amway-corp-astellas-pharma-inc-estrellas-life-sciences-pvt-ltd-are-some-of-the-major-companies-in-the-market---technavio-301959371.html",
            "time_published": "20231017T211500",
            "authors": [],
            "summary": "Weight Management Market size to grow by USD 85.5 billion from 2022-2027| Amway Corp., Astellas Pharma Inc ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.336671,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HLF",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NATR",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALPMF",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NUS",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLAPF",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.098033",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  to Acquire Hypertension Drug for $1.3B",
            "url": "https://www.zacks.com/stock/news/2167301/novo-nordisk-nvo-to-acquire-hypertension-drug-for-13b",
            "time_published": "20231017T143100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.048247,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.043662",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACAD",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.063705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.063705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.528475",
                    "ticker_sentiment_score": "-0.04402",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's what Ozempic, ASML and India's fintech industry all have in common - and how one ETF takes advantage of all three",
            "url": "https://www.marketwatch.com/story/heres-what-ozempic-asml-and-indias-fintech-industry-all-have-in-common-and-how-one-etf-takes-advantage-of-all-three-70d1260a",
            "time_published": "20231017T125500",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "C Worldwide Thematic Specialist Morten Springborg says his firm has outperformed by taking a much longer-term approach than is usual for money managers.",
            "banner_image": "https://images.mktw.net/im-869481/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996718"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.140845,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SMAWF",
                    "relevance_score": "0.030958",
                    "ticker_sentiment_score": "0.104133",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.030958",
                    "ticker_sentiment_score": "-0.170054",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.046002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HDB",
                    "relevance_score": "0.123367",
                    "ticker_sentiment_score": "0.048738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.068006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ATLKY",
                    "relevance_score": "0.030958",
                    "ticker_sentiment_score": "0.020023",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.153863",
                    "ticker_sentiment_score": "0.054463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.092688",
                    "ticker_sentiment_score": "-0.029482",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is FlexShares International Quality Dividend ETF  ( IQDF )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2166893/is-flexshares-international-quality-dividend-etf-iqdf-a-strong-etf-right-now",
            "time_published": "20231017T102006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.231539,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BHP",
                    "relevance_score": "0.110209",
                    "ticker_sentiment_score": "0.046946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTRS",
                    "relevance_score": "0.270973",
                    "ticker_sentiment_score": "0.211365",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RBCPF",
                    "relevance_score": "0.055236",
                    "ticker_sentiment_score": "0.042881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055236",
                    "ticker_sentiment_score": "0.042881",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.",
            "url": "https://www.fool.com/investing/2023/10/17/ozempic-sales-are-skyrocketing-faster-than-expecte/",
            "time_published": "20231017T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "What's good for Novo Nordisk's Ozempic is also good for Eli Lilly's Mounjaro.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.309608,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.455525",
                    "ticker_sentiment_score": "0.390074",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.350564",
                    "ticker_sentiment_score": "0.462387",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "New Playground, New Court, New Classroom? Thank Ozempic.",
            "url": "https://www.wsj.com/health/pharma/those-new-pickleball-courts-thank-ozempic-581899f3",
            "time_published": "20231017T093000",
            "authors": [
                "Peter Loftus"
            ],
            "summary": "Philanthropies with large stakes in weight-loss drugmakers Eli Lilly and Novo Nordisk have surged in value and are now among the biggest in the world.",
            "banner_image": "https://images.wsj.net/im-869996/social",
            "source": "Wall Street Journal",
            "category_within_source": "Business",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.461945,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.468029",
                    "ticker_sentiment_score": "0.633946",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S  ( NYSE:NVO )  Upgraded by StockNews.com to \"Strong-Buy\"",
            "url": "https://www.defenseworld.net/2023/10/17/novo-nordisk-a-s-nysenvo-upgraded-by-stocknews-com-to-strong-buy.html",
            "time_published": "20231017T082248",
            "authors": [
                "Defense World Staff"
            ],
            "summary": "Novo Nordisk A/S ( NYSE:NVO ) Upgraded by StockNews.com to ... Defense World ...",
            "banner_image": "https://www.marketbeat.com/logos/novo-nordisk-logo.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.defenseworld.net",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.205282,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.089113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.87047",
                    "ticker_sentiment_score": "0.350394",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Analysis: Priced for earnings recession, European equities could weather storm",
            "url": "https://www.reuters.com/markets/asia/priced-earnings-recession-european-equities-could-weather-storm-2023-10-17/",
            "time_published": "20231017T070500",
            "authors": [
                "Joice Alves"
            ],
            "summary": "The German share price index DAX graph is pictured at the Frankfurt stock exchange after risks have climbed to multi-month highs in recent days as concerns over contagion from the collapse of Silicon Valley Bank and instability at European bank Credit Suisse gripped the markets, in Frankfurt, ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/7NWJ4KMHXVM3POJEAHNPQEQ3UQ.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999976"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.988787"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.041791,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "0.047022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "0.101635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "0.260772",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "-0.086924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "-0.086924",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Stock Falls Amid Market Uptick: What Investors Need to Know",
            "url": "https://www.zacks.com/stock/news/2166769/novo-nordisk-nvo-stock-falls-amid-market-uptick-what-investors-need-to-know",
            "time_published": "20231016T215017",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default38.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.132167,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.612033",
                    "ticker_sentiment_score": "0.283597",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Is Alzheimer's Player Prothena Stock Trading Higher Today? - Prothena Corp  ( NASDAQ:PRTA ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35269372/why-is-alzheimers-player-prothena-stock-trading-higher-today",
            "time_published": "20231016T152800",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Prothena Corporation plc PRTA is reportedly talking to advisors, potentially preparing for a sale. The closely watched Alzheimer's player is due to report key data expected in the coming months.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/aapharma_4.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.122411,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.279015",
                    "ticker_sentiment_score": "0.208736",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.383998",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.115093",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion-Expanding Ozempic Maker's Arsenal",
            "url": "https://www.forbes.com/sites/tylerroush/2023/10/16/novo-nordisk-buys-hypertension-drug-ocedurenone-for-13-billion-expanding-ozempic-makers-arsenal/",
            "time_published": "20231016T141207",
            "authors": [
                "Ty Roush"
            ],
            "summary": "The Danish firm said the drug has \"best-in-class potential\" for treating uncontrolled hypertension.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/652d4457032a9ecae4ac363f/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "Business",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.073066,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.502207",
                    "ticker_sentiment_score": "0.055476",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Raises Sales Outlook for 2023, Shares Gain",
            "url": "https://www.zacks.com/stock/news/2166475/novo-nordisk-nvo-raises-sales-outlook-for-2023-shares-gain",
            "time_published": "20231016T125200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.227746,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.068932",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.34974",
                    "ticker_sentiment_score": "0.424589",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ACAD",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.068932",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - Share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/10/16/2760634/0/en/Novo-Nordisk-A-S-Share-repurchase-programme.html",
            "time_published": "20231016T120900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 16 October 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus",
            "url": "https://www.zacks.com/stock/news/2166368/beat-the-market-the-zacks-way-novo-nordisk-makemytrip-fastenal-in-focus",
            "time_published": "20231016T120800",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999612"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                }
            ],
            "overall_sentiment_score": 0.134156,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CELH",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.212549",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CORT",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.079085",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.097721",
                    "ticker_sentiment_score": "0.106695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.047169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSN",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.173751",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FAST",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.061177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.061177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.10113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SP",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.173751",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MMYT",
                    "relevance_score": "0.065238",
                    "ticker_sentiment_score": "0.205531",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Can Novo Nordisk's Success Really Be Trouble for Denmark?",
            "url": "https://www.theatlantic.com/ideas/archive/2023/10/novo-nordisk-ozempic-wegovy-denmark/675638/",
            "time_published": "20231016T113000",
            "authors": [
                "James Surowiecki"
            ],
            "summary": "Is Novo Nordisk's Success Really Trouble for Denmark? The Atlantic ...",
            "banner_image": "https://cdn.theatlantic.com/thumbor/izqNbkwZT_0PDbsHX8h_UoENqXk=/0x0:2000x1125/960x540/media/img/mt/2023/10/denmark_economy_final_horz/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.063035,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.03878",
                    "ticker_sentiment_score": "-0.084829",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.266412",
                    "ticker_sentiment_score": "0.041388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.338325",
                    "ticker_sentiment_score": "-0.037591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.03878",
                    "ticker_sentiment_score": "0.127927",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.077468",
                    "ticker_sentiment_score": "0.13337",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Modifi Bio Raises Additional $4.3 Million in Seed Funding",
            "url": "https://www.benzinga.com/pressreleases/23/10/g35262839/modifi-bio-raises-additional-4-3-million-in-seed-funding",
            "time_published": "20231016T110000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW HAVEN, Conn., Oct. 16, 2023 ( GLOBE NEWSWIRE ) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": 0.1431,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.049992",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences",
            "url": "https://www.globenewswire.com/news-release/2023/10/16/2760508/0/en/Novo-Nordisk-to-acquire-ocedurenone-for-uncontrolled-hypertension-from-KBP-Biosciences.html",
            "time_published": "20231016T110000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark and Singapore, 16 October 2023 - Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.019396,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029839",
                    "ticker_sentiment_score": "0.052827",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.029839",
                    "ticker_sentiment_score": "0.052827",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.291644",
                    "ticker_sentiment_score": "0.050266",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk in $1.3 bln deal to buy hypertension drug",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-13-bln-deal-buy-hypertension-drug-kbp-biosciences-2023-10-16/",
            "time_published": "20231016T001513",
            "authors": [
                "Reuters"
            ],
            "summary": "Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QBLATG4IHBMOVE45EG3VUK7C5U.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.031002,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.481177",
                    "ticker_sentiment_score": "0.101343",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Barron's Weekend Stock Picks: Truist Financial, Groupon And Nvidia's Rising Stock",
            "url": "https://markets.businessinsider.com/news/stocks/barron-s-weekend-stock-picks-truist-financial-groupon-and-nvidia-s-rising-stock-1032705995",
            "time_published": "20231015T175559",
            "authors": [],
            "summary": "Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.",
            "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/10/15/truist.jpg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.398651,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GRPN",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.187926",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TFC",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "-0.058605",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.370367",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.256862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.617515",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.079122",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Barron's Weekend Stock Picks: Truist Financial, Groupon And Nvidia's Rising Stock - NVIDIA  ( NASDAQ:NVDA ) , Groupon  ( NASDAQ:GRPN ) ",
            "url": "https://www.benzinga.com/news/23/10/35256991/barrons-weekend-stock-picks-truist-financial-groupon-and-nvidias-rising-stock",
            "time_published": "20231015T173858",
            "authors": [
                "Justin Chan"
            ],
            "summary": "Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/15/truist.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.371006,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GRPN",
                    "relevance_score": "0.255641",
                    "ticker_sentiment_score": "0.304741",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TFC",
                    "relevance_score": "0.375251",
                    "ticker_sentiment_score": "0.026508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.375251",
                    "ticker_sentiment_score": "0.499525",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.375251",
                    "ticker_sentiment_score": "0.756221",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.255641",
                    "ticker_sentiment_score": "0.131168",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds",
            "url": "https://apnews.com/article/mounjaro-obesity-weight-loss-tirzepatide-ac4151fdfcd6ac17f502d1a14af4fff5",
            "time_published": "20231015T160400",
            "authors": [
                "JONEL ALECCIA"
            ],
            "summary": "The medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight, or about 60 pounds on average, when combined with intensive diet and exercise, a new study shows.",
            "banner_image": "https://dims.apnews.com/dims4/default/d89b2cc/2147483647/strip/true/crop/3000x1998+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F38%2Fd3%2F6d67992d2165ee507184886c910c%2Fa999d5b109e44cf2a79ee855c87f0156",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.033093,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHH",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.167026",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.088393",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Walmart Stock Is Worth a Closer Look for Artificial Intelligence Investors. Here's Why.",
            "url": "https://www.fool.com/investing/2023/10/15/walmart-stock-is-worth-a-look-for-ai-investors/",
            "time_published": "20231015T154100",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Walmart is studying changes in shopping patterns among those who take Ozempic and those who do not.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750330%2Fshoppers-in-a-grocery-store.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.084932,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "-0.06801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "0.124308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "-0.002884",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "0.017576",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.641083",
                    "ticker_sentiment_score": "0.076359",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Split Watch: Is Chipotle Next?",
            "url": "https://www.fool.com/investing/2023/10/15/stock-split-watch-is-chipotle-next/",
            "time_published": "20231015T133000",
            "authors": [
                "Collin Brantmeyer"
            ],
            "summary": "Here is one stock that could potentially benefit from a stock split.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749219%2Feating-tacos.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.922939"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.189872,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "YUM",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "-0.100008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "-0.009055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.121959",
                    "ticker_sentiment_score": "0.029694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "-0.009055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "-0.009055",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'Miracle drug' euphoria: Experts warn widespread use of weight loss medicine faces major hurdles",
            "url": "https://www.cnbc.com/2023/10/14/obesity-medicine-euphoria-warning-experts-tackle-miracle-drugs.html",
            "time_published": "20231014T173550",
            "authors": [
                "Anna Gleason"
            ],
            "summary": "Two experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly's obesity drugs.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107315631-16970623211697062317-31559422191-1080pnbcnews.jpg?v=1697063031&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Finance",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.128694,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.425541",
                    "ticker_sentiment_score": "0.160225",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs",
            "url": "https://www.fool.com/investing/2023/10/14/1-big-risk-facing-ozempic-wegovy-and-other-glp-1/",
            "time_published": "20231014T142300",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Can concerns about side effects derail the growth of these incredibly popular drugs?",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.072901,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.321393",
                    "ticker_sentiment_score": "0.059061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.10158",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Are Ozempic and Similar Treatments Impacting Food and Beverage Stocks? Here's What Pepsi's CFO Said About It",
            "url": "https://www.fool.com/investing/2023/10/14/are-ozempic-and-similar-treatments-impacting-food/",
            "time_published": "20231014T120300",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "PepsiCo's Q3 earnings may have shed some light on the long-standing speculation about Ozempic's impact on consumer staples.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750584%2Fgettyimages-1630177922.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                }
            ],
            "overall_sentiment_score": 0.185148,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.066784",
                    "ticker_sentiment_score": "0.065477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.38489",
                    "ticker_sentiment_score": "0.263266",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.066784",
                    "ticker_sentiment_score": "0.025221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.198493",
                    "ticker_sentiment_score": "0.103525",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The stock market is getting Ozempic'ed",
            "url": "https://markets.businessinsider.com/news/stocks/stock-market-outlook-ozempic-wegovy-glp1-weight-loss-drugs-investing-2023-10",
            "time_published": "20231014T090200",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "How Weight-Loss Drugs Like Ozempic Will Alter the Stock Market's Outlook - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990893"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.146555,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.075334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "-0.103185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "-0.103185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TNDM",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "-0.023285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.105115",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.121673",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "-0.013314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.053955",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "-0.103185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "0.053955",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "-0.103185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.033052",
                    "ticker_sentiment_score": "-0.023285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "-0.036037",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Ups Outlook Amid Demand For Weight Loss Drug - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/10/35251869/novo-nordisk-ups-outlook-amid-surging-demand-for-weight-loss-drug-wegovy-ozempic",
            "time_published": "20231014T042325",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Danish pharmaceutical company Novo Nordisk NVO has revised its full-year sales and operating profit outlook.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Ozempic_maker_Novo_Nordisk_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.297631,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.694939",
                    "ticker_sentiment_score": "0.604945",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Raced Higher Today",
            "url": "https://www.fool.com/investing/2023/10/13/why-novo-nordisk-stock-raced-higher-today/",
            "time_published": "20231013T205639",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "Wegovy and Ozempic should continue to be hot items at the pharmacy.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.398119,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.801457",
                    "ticker_sentiment_score": "0.612672",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "This Is What Whales Are Betting On Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/10/35249080/this-is-what-whales-are-betting-on-novo-nordisk",
            "time_published": "20231013T204631",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 51 strange trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.150268,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.783279",
                    "ticker_sentiment_score": "0.413348",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Jamie Dimon says it's 'the most dangerous time the world has seen in decades.' Here are all the ripple effects.",
            "url": "https://www.marketwatch.com/story/how-to-find-financial-opportunities-in-what-jamie-dimon-calls-the-most-dangerous-time-the-world-has-seen-in-decades-8a363023",
            "time_published": "20231013T163000",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Also, hope for housing, close looks at choices for bond investors, a busted IPO and sound advice from the Moneyist.",
            "banner_image": "https://images.mktw.net/im-867562?width=700&height=466",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.079738,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.136302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.253983",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.136302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.099202",
                    "ticker_sentiment_score": "0.103922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDFN",
                    "relevance_score": "0.033144",
                    "ticker_sentiment_score": "0.199051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.253983",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "-0.027173",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "UnitedHealth earnings beat estimates as company again raises guidance",
            "url": "https://www.marketwatch.com/story/unitedhealth-q3-earnings-beat-estimates-as-company-again-raises-guidance-64b51665",
            "time_published": "20231013T160600",
            "authors": [
                "",
                "Ciara Linnane",
                "Eleanor Laise"
            ],
            "summary": "Insurance giant takes aim at weight-loss drug prices, saying cost will limit adoption.",
            "banner_image": "https://images.mktw.net/im-626609/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.170053,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.079392",
                    "ticker_sentiment_score": "0.100567",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.235062",
                    "ticker_sentiment_score": "0.414095",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "THC",
                    "relevance_score": "0.158",
                    "ticker_sentiment_score": "-0.1671",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.574748",
                    "ticker_sentiment_score": "0.16914",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "IMCD nominates new Supervisory Board member and publishes EGM convocation",
            "url": "https://www.globenewswire.com/news-release/2023/10/13/2760068/0/en/IMCD-nominates-new-Supervisory-Board-member-and-publishes-EGM-convocation.html",
            "time_published": "20231013T160000",
            "authors": [
                "IMCD N.V."
            ],
            "summary": "ROTTERDAM, The Netherlands ( 13 October 2023, 18:00 CEST ) - IMCD N.V. ( \"IMCD\" or \"Company\" ) , a global leading distribution partner, formulator of speciality chemicals and ingredients, announces that its Supervisory Board has nominated Mrs. Dorthe Mikkelsen for appointment as member of the ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/62371a7c-7527-412b-8714-ae6e2fa2e2d9",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.23555,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IMDZF",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.290587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.017351",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.",
            "url": "https://www.marketwatch.com/story/what-exactly-are-patients-taking-new-weight-loss-drugs-eating-and-what-are-they-avoiding-bernstein-asked-them-3d523d3d",
            "time_published": "20231013T153400",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Bernstein analyzed online data to determine what people taking Ozempic and Wegovy are eating and what are they cutting out of their diets.",
            "banner_image": "https://images.mktw.net/im-868112?width=700&height=415",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.109403,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GIS",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.098113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMPL",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.10844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.098113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPB",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "-0.047627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.0428",
                    "ticker_sentiment_score": "-0.123497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.109358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.098113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TWNK",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.169975",
                    "ticker_sentiment_score": "0.093824",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "K",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "0.098113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.0428",
                    "ticker_sentiment_score": "-0.059562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSN",
                    "relevance_score": "0.085476",
                    "ticker_sentiment_score": "-0.047627",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Rallies, Hits Resistance: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rallies-hits-resistance-novo-nordisk-jpmorgan-exxon-in-focus/",
            "time_published": "20231013T152200",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "Stock Market Rallies, Hits Resistance. Novo Nordisk, JPMorgan ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2016/03/BIGPIC-032316-shutterstock.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999819"
                }
            ],
            "overall_sentiment_score": -0.049165,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.069711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "F",
                    "relevance_score": "0.073773",
                    "ticker_sentiment_score": "0.178146",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "-0.020212",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "-0.029637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "-0.157722",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.073773",
                    "ticker_sentiment_score": "-0.067843",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "-0.108098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "-0.06527",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.069711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.073773",
                    "ticker_sentiment_score": "-0.160534",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "0.093971",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "-0.029637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.085682",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic",
            "url": "https://www.cnbc.com/2023/10/13/novo-nordisk-hikes-outlook-on-soaring-demand-for-wegovy-ozempic.html",
            "time_published": "20231013T150544",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107297618-1694173882242-gettyimages-1581638847-arriens-ozempicm230806_nplWH.jpeg?v=1697209758&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.232414,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.765213",
                    "ticker_sentiment_score": "0.471172",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Weight Loss Drug Maker Is Making Money Hand Over Fist - And Just Raised Its Profit Forecast - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35241823/ozempic-weight-loss-drug-maker-is-making-money-hand-over-fist-and-just-raised-its-profit-forecast",
            "time_published": "20231013T143112",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO raised its FY23 guidance as sales of its blockbuster obesity and weight-loss drugs continue to surge. The success of the weight-loss drug Wegovy and diabetes treatment Ozempic has helped the Danish pharmaceutical giant surge to make it Europe's most valuable company.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/13/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.327686,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.640349",
                    "ticker_sentiment_score": "0.540149",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Momo Buys On Iran Hinting At Second Front And Israel Issuing An Impossible Evacuation Order - JPMorgan Chase  ( NYSE:JPM ) ",
            "url": "https://www.benzinga.com/markets/23/10/35242061/momo-buys-on-iran-hinting-at-second-front-and-israel-issuing-an-impossible-evacuation-order",
            "time_published": "20231013T143030",
            "authors": [
                "The Arora Report"
            ],
            "summary": "To gain an edge, this is what you need to know today. Please click here for a chart of SPDR S&P 500 ETF Trust SPY which represents the benchmark stock market index S&P 500 ( SPX ) . The chart shows that the stock market pulled back to the top band of the top support zone on rising yields.",
            "banner_image": "https://cdn.benzinga.com/files/nicholas-cappello-wb63zqj5gne-unsplash_11_22.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.245115,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.126617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.126617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.126617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.126617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.104835",
                    "ticker_sentiment_score": "0.203487",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PNC",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.243734",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.139467",
                    "ticker_sentiment_score": "0.171594",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.154912",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.035035",
                    "ticker_sentiment_score": "0.3556",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.243734",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.126617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.126617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.243734",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.070002",
                    "ticker_sentiment_score": "0.154912",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy",
            "url": "https://www.marketwatch.com/story/novo-nordisk-boosts-sales-and-profit-outlook-buoyed-by-ozempic-and-wegovy-ef589d0e",
            "time_published": "20231013T142200",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Brighter projections may suggest more supply of popular weight-loss drugs by year end, analysts say.",
            "banner_image": "https://images.mktw.net/im-863819/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.355763,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.509589",
                    "ticker_sentiment_score": "0.453917",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates",
            "url": "https://www.zacks.com/stock/news/2165526/pharma-stock-roundup-lly-meets-ibd-study-goal-pfe-mrk-give-cancer-pipeline-updates",
            "time_published": "20231013T134100",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.09506,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "-0.068286",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "-0.10015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "-0.11971",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk raises outlook for full-year sales, operating profit",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-raises-outlook-full-year-sales-operating-profit-2023-10-13/",
            "time_published": "20231013T125624",
            "authors": [
                "Reuters"
            ],
            "summary": "Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QBLATG4IHBMOVE45EG3VUK7C5U.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.339253,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.629492",
                    "ticker_sentiment_score": "0.322947",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk raises sales and operating profit outlook for 2023",
            "url": "https://www.globenewswire.com/news-release/2023/10/13/2759958/0/en/Novo-Nordisk-raises-sales-and-operating-profit-outlook-for-2023.html",
            "time_published": "20231013T124800",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 13 October 2023 - Novo Nordisk today announced that the sales and operating profit growth at constant exchange rates ( CER ) for the first nine months of 2023 and that the full-year sales and operating profit outlook at CER have been raised.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.120483,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.051768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.051768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.546745",
                    "ticker_sentiment_score": "0.267175",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic's impact on kidney patients limited, Dialysis Provider DaVita says",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempics-impact-on-kidney-patients-limited-dialysis-provider-davita-says/3271890/",
            "time_published": "20231013T095518",
            "authors": [
                "Bloomberg"
            ],
            "summary": "DaVita Inc. downplayed the impact of GLP-1 drugs like Novo Nordisk A/S's Ozempic after study results in kidney patients sent the dialysis-provider's stock tumbling. The Denver-based company said in a statement that it's \"eager to understand the results of the study\" in which Ozempic met an ...",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/10/vitamins-g81bff71f1_1920.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.064736,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAX",
                    "relevance_score": "0.156461",
                    "ticker_sentiment_score": "0.096228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.156461",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.44622",
                    "ticker_sentiment_score": "-0.153876",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.156461",
                    "ticker_sentiment_score": "-0.162931",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Why Shares of Insulet Dropped This Week",
            "url": "https://www.fool.com/investing/2023/10/12/why-shares-of-insulet-dropped-this-week/",
            "time_published": "20231012T214053",
            "authors": [
                "James Halley"
            ],
            "summary": "Positive news regarding diabetes therapy Ozempic worried investors.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.095949,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.061375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.59016",
                    "ticker_sentiment_score": "0.151349",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TNDM",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "-0.043105",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "-0.043105",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "-0.092374",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Surprising Opportunity Driving Vertex Stock To A Record High",
            "url": "https://www.investors.com/research/the-new-america/vrtx-stock-breaks-out-to-a-record-high-the-surprising-opportunity/",
            "time_published": "20231012T191700",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Almost three-quarters of prescribed pain meds are opioids, and Vertex Pharmaceuticals ( VRTX ) could change that, an analyst said before VRTX stock broke out to a record high Thursday. Leerink Partners analyst David Risinger drew parallels between the drug development arc for obesity drugs and ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/wNAvertPersc101623.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": -0.12148,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.50287",
                    "ticker_sentiment_score": "0.052359",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.208107",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.208107",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "-0.117904",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Shares of ProKidney Were Dropping Thursday",
            "url": "https://www.fool.com/investing/2023/10/12/why-shares-of-prokidney-were-dropping-thursday/",
            "time_published": "20231012T190523",
            "authors": [
                "Jim Halley"
            ],
            "summary": "Two factors led to the stock's slide on Thursday.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.100745,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "-0.018975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PROK",
                    "relevance_score": "0.517168",
                    "ticker_sentiment_score": "0.032621",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "DaVita plays down Ozempic's potential in treating kidney disease",
            "url": "https://www.marketwatch.com/story/davita-says-news-of-ozempics-potential-in-treating-kidney-disease-may-have-only-limited-impact-for-patients-says-further-studies-will-be-needed-641f67f1",
            "time_published": "20231012T164200",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Dialysis company DaVita is not convinced a Novo Nordisk trial's findings relating to its Ozempic treatment will be borne out over time.",
            "banner_image": "https://images.mktw.net/im-867335/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DVA",
                    "relevance_score": "0.47379",
                    "ticker_sentiment_score": "0.009241",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.084127",
                    "ticker_sentiment_score": "-0.144625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.248682",
                    "ticker_sentiment_score": "-0.129087",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Ingredient Gives Maker Novo Nordisk's Kidney Outcomes Trial A Positive Result: How Will This Affect the Industry? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35223055/novo-nordisks-kidney-outcomes-trial-has-broad-industry-implications",
            "time_published": "20231012T162353",
            "authors": [
                "Adam Eckert"
            ],
            "summary": "Novo Nordisk A/S NVO shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on early signs of efficacy. The study has implications for other drugmakers including Eli Lilly And Co LLY and DaVita Inc DVA.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/12/original-2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.141322,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.447428",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.220472",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.689652",
                    "ticker_sentiment_score": "0.155398",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.423775",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Fresenius Medical  ( FMS )  Sinks on Potential Rise in Competition",
            "url": "https://www.zacks.com/stock/news/2165136/fresenius-medical-fms-sinks-on-potential-rise-in-competition",
            "time_published": "20231012T161800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.075495,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MEDP",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.112252",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.505874",
                    "ticker_sentiment_score": "0.055229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALGN",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.129428",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCK",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.0573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.267559",
                    "ticker_sentiment_score": "0.073217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.135729",
                    "ticker_sentiment_score": "0.166605",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  Up on NVO's Ozempic Early Success in Kidney Study",
            "url": "https://www.zacks.com/stock/news/2165095/lilly-lly-up-on-nvos-ozempic-early-success-in-kidney-study",
            "time_published": "20231012T161300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.156478,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.43494",
                    "ticker_sentiment_score": "0.235223",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AUPH",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.15358",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "-0.039629",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALPN",
                    "relevance_score": "0.257668",
                    "ticker_sentiment_score": "0.217631",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Dow Jones Falls As Nasdaq Holds Key Level; Bank Earnings Loom",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-after-economic-data-as-nasdaq-holds-key-level-bank-earnings-loom/",
            "time_published": "20231012T150700",
            "authors": [
                "Investor's Business Daily",
                "VIDYA RAMAKRISHNAN"
            ],
            "summary": "Dow Jones Falls As Nasdaq Holds Key Level. Bank Earnings Loom Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-GlobalFoundries-nasdaq-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999491"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99246"
                }
            ],
            "overall_sentiment_score": 0.108398,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.117321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.160705",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EG",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.152018",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.117321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.117321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.199842",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.152018",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.019318",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.115069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DPZ",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.098951",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DMPZF",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.089009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.152018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.129238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FAST",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.140081",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss drugs are no match for the might of big food",
            "url": "https://www.economist.com/business/2023/10/12/weight-loss-drugs-are-no-match-for-the-might-of-big-food",
            "time_published": "20231012T140445",
            "authors": [
                "The Economist"
            ],
            "summary": "The world is as addicted to fattening foods as it is to fossil fuels ...",
            "banner_image": "https://www.economist.com/img/b/1424/1873/90/media-assets/image/20231014_DE_US.jpg",
            "source": "The Economist",
            "category_within_source": "Business",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.067762,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "COST",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "0.056855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "0.056855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "0.056855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "0.056855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.07157",
                    "ticker_sentiment_score": "-0.021393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.07157",
                    "ticker_sentiment_score": "0.059554",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  Moves 4.5% Higher: Will This Strength Last?",
            "url": "https://www.zacks.com/stock/news/2164784/lilly-lly-moves-45-higher-will-this-strength-last",
            "time_published": "20231012T130400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default52.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.156527,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.551295",
                    "ticker_sentiment_score": "0.13081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.045165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.551295",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Rise With CPI Inflation Due",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-at-key-levels-as-inflation-data-looms-novo-nordisk-soars/",
            "time_published": "20231012T120700",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures Rise: Market Rally At Key Levels As Inflation ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/FAP2020-bull-123019-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.998626"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.002419,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.108222",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.038691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.027134",
                    "ticker_sentiment_score": "0.215241",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "F",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "-0.035159",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.108222",
                    "ticker_sentiment_score": "0.014356",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.135043",
                    "ticker_sentiment_score": "0.057918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.006935",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.027134",
                    "ticker_sentiment_score": "0.071256",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STRL",
                    "relevance_score": "0.054236",
                    "ticker_sentiment_score": "0.134779",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.108222",
                    "ticker_sentiment_score": "-0.158279",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.054236",
                    "ticker_sentiment_score": "-0.161835",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FOREX:GBP",
                    "relevance_score": "0.027134",
                    "ticker_sentiment_score": "0.125029",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35216055/novo-nordisks-popular-diabetes-drug-ozempic-faces-counterfeit-threat-in-germany",
            "time_published": "20231012T113604",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Germany's federal drug regulator, BfArM, has warned pharmacies and drug distributors in response to discovering counterfeit batches of Novo Nordisk's NVO diabetes medication, Ozempic.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/12/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.121527,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.1097",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Zacks Investment Ideas feature highlights: Nvidia, Tesla and Novo Nordisk",
            "url": "https://www.zacks.com/stock/news/2164737/zacks-investment-ideas-feature-highlights-nvidia-tesla-and-novo-nordisk",
            "time_published": "20231012T113600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Nvidia, Tesla and Novo Nordisk are part of the Zacks Investment Ideas article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/107.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.168791,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.263036",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.533481",
                    "ticker_sentiment_score": "0.344718",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.358413",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk warns consumers of surge in its fake weight loss drugs Ozempic, Wegovy",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/novo-nordisk-warns-consumers-of-surge-in-its-fake-weight-loss-drugs-ozempic-wegovy/3270911/",
            "time_published": "20231012T112517",
            "authors": [
                "Health Desk"
            ],
            "summary": "Novo Nordisk on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online. According to a report by Reuters, illegal traders are trying to take advantage of their huge popularity, putting users' health at risk.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/10/syring-2.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.066424,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.053878",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk warns online offers of fake Ozempic, Wegovy are on the rise",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-warns-online-offers-fake-ozempic-wegovy-are-rise-2023-10-12/",
            "time_published": "20231012T111500",
            "authors": [
                "Ludwig Burger",
                "Maggie Fick"
            ],
            "summary": "Oct 12 ( Reuters ) - Novo Nordisk ( NOVOb.CO ) on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online as illegal traders seek to take advantage of their huge popularity, putting users' health at risk.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RONZCIEAUZJGZBZPKYLAOQEGPU.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.06643,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.054014",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo drugs Ozempic and Wegovy are shaking up stock markets again",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/novo-drugs-ozempic-and-wegovy-are-shaking-up-stock-markets-again/3270796/",
            "time_published": "20231012T105154",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Novo Nordisk, the Danish company, now Europe's largest by market value, said late Tuesday it was halting a study that looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early. The news hit shares of the world's biggest kidney dialysis ...",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/10/pills-g5a602a81d_1920-1.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.133369,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WW",
                    "relevance_score": "0.206685",
                    "ticker_sentiment_score": "0.268136",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.012125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.118925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.175207",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.118925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.107321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.118925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.118925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.107321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.118925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.012974",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "European stocks trim early gains after US CPI data",
            "url": "https://www.reuters.com/markets/europe/european-stocks-touch-three-week-highs-easing-interest-rate-concerns-2023-10-12/",
            "time_published": "20231012T093100",
            "authors": [
                "Siddarth S",
                "Sruthi Shankar",
                "Shristi A"
            ],
            "summary": "European stocks touch three-week highs on rate outlook optimism ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/7XBXB4KEWZMUFGJF2EHGFA6WAU.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.217946,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "RSTGF",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.074989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IBKR",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.261366",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "-0.081353",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLFDF",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.304743",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.180171",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock's Dream Run May Not Be Over Yet - The Future Fund Active ETF  ( ARCA:FFND ) , Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35213501/eli-lilly-to-fly-higher-fund-manager-gary-black-envisions-blockbuster-potential-for",
            "time_published": "20231012T084057",
            "authors": [
                "Shanthi Rexaline"
            ],
            "summary": "Eli Lilly & Co. LLY has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black weighed in on the stock's run-up and its future trajectory.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Eli_Lilly_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.120341,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.68471",
                    "ticker_sentiment_score": "0.144027",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "0.016091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "0.03599",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.198221",
                    "ticker_sentiment_score": "0.133554",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/australias-csl-tanks-novo-nordisks-kidney-trial-success-stokes-competition-2023-10-12/",
            "time_published": "20231012T055414",
            "authors": [
                "Archishma Iyer"
            ],
            "summary": "Oct 12 ( Reuters ) - Shares of biotechnology firm CSL ( CSL.AX ) fell to a four-year low on Thursday, after rival Novo Nordisk's ( NOVOb.CO ) Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients.",
            "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=160",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.152451,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "RMD",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.19268",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.136873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.136873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SKHCF",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.19268",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Tempest Therapeutics, Microsoft, Birkenstock, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Microsoft  ( NASDAQ:MSFT ) , Tesla  ( NASDAQ:TSLA ) , Novo Nordisk  ( NYSE:NVO ) , Tempest Therapeutics  ( NASDAQ:TPST ) ",
            "url": "https://www.benzinga.com/markets/equities/23/10/35210558/tempest-therapeutics-microsoft-birkenstock-novo-nordisk-tesla-why-these-5-stocks-are-on-investor",
            "time_published": "20231012T021655",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Major U.S. stock indices ended in the green on Wednesday, with the Nasdaq Composite marking notable gains of nearly 100 points. The Dow also ended Wednesday's session in the green, while the S&P 500 experienced a slight uptick.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_WHYFRAME_on_Shutterstock_24.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.146919,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.28008",
                    "ticker_sentiment_score": "0.263277",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.137116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TPST",
                    "relevance_score": "0.28008",
                    "ticker_sentiment_score": "0.058801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.28008",
                    "ticker_sentiment_score": "-0.277851",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.28008",
                    "ticker_sentiment_score": "0.208539",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Investors Punished Baxter International Stock Today",
            "url": "https://www.fool.com/investing/2023/10/11/why-investors-punished-baxter-international-stock/",
            "time_published": "20231011T224931",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The latest data from the lab could spell trouble for the company.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.045507,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAX",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "0.156057",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.431065",
                    "ticker_sentiment_score": "0.031803",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Shares of Ardelyx Were Down Wednesday",
            "url": "https://www.fool.com/investing/2023/10/11/why-shares-of-ardelyx-were-down-wednesday/",
            "time_published": "20231011T201700",
            "authors": [
                "Jim Halley"
            ],
            "summary": "The company's hopes for approval of a drug to treat chronic kidney disease took a hit.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.114193,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.246584",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARDX",
                    "relevance_score": "0.577527",
                    "ticker_sentiment_score": "0.157324",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The 3 Widest Competitive Moats on Wall Street",
            "url": "https://www.zacks.com/commentary/2164433/the-3-widest-competitive-moats-on-wall-street",
            "time_published": "20231011T182200",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/22/35721.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.163763,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "0.287992",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.429541",
                    "ticker_sentiment_score": "0.308779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.22335",
                    "ticker_sentiment_score": "0.273739",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "0.07639",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "-0.036125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "-0.036125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "-0.036125",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and more",
            "url": "https://www.cnbc.com/2023/10/11/stocks-making-the-biggest-moves-midday-.html",
            "time_published": "20231011T165442",
            "authors": [
                "Michelle Fox"
            ],
            "summary": "These are some of the stocks posting the largest moves midday.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107277196-16903924192023-03-29t000000z_1584578494_rc2w30a2jx4l_rtrmadp_0_usa-health.jpeg?v=1697043282&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.335833,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HUM",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.119642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.297062",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALLY",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.126832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.092966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.157686",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.137589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.297062",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SHLS",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.156249",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLUG",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.117588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.156249",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.137589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.297062",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Dialysis Stocks Plunged Today",
            "url": "https://www.fool.com/investing/2023/10/11/why-dialysis-stocks-plunged-today/",
            "time_published": "20231011T165159",
            "authors": [
                "Steve Symington"
            ],
            "summary": "Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here's what investors need to know.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.050637,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "0.09184",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "0.070504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "-0.114016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.613172",
                    "ticker_sentiment_score": "-0.047151",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.094172",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Shares of Fresenius Medical Care Were Dropping on Wednesday",
            "url": "https://www.fool.com/investing/2023/10/11/why-shares-of-fresenius-medical-care-were-dropping/",
            "time_published": "20231011T161808",
            "authors": [
                "Jim Halley"
            ],
            "summary": "Positive trial news for a kidney failure drug could cut into business for dialysis therapies companies such as Fresenius.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.080005,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAX",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.018719",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.137778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.018719",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.018719",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Eli Lilly Stock Wednesday? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/10/35197403/whats-going-on-with-eli-lilly-stock-wednesday",
            "time_published": "20231011T161603",
            "authors": [
                "Adam Eckert"
            ],
            "summary": "Eli Lilly And Co LLY shares are trading higher Wednesday. The stock appears to be moving alongside Novo Nordisk NVO shares after the drugmaker halted trials on early signs of efficiency.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/11/us_devicefront_5.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.096302,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.810649",
                    "ticker_sentiment_score": "0.159772",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.426225",
                    "ticker_sentiment_score": "0.014121",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.426225",
                    "ticker_sentiment_score": "0.433376",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "German drug regulator to coordinate investigation into fake Ozempic",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/german-drug-regulator-coordinate-investigation-into-fake-ozempic-2023-10-11/",
            "time_published": "20231011T154900",
            "authors": [
                "Reuters"
            ],
            "summary": "German drug regulator to coordinate investigation into fake ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/X2KFU6HOUBKRZBZFYEA2CFBIW4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.037271,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.345674",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Is Jumping Today",
            "url": "https://www.fool.com/investing/2023/10/11/why-eli-lilly-stock-is-jumping-today/",
            "time_published": "20231011T154531",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Good news for Novo Nordisk's Ozempic could be good news for Lilly's Mounjaro.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.272474,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.101806",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.279015",
                    "ticker_sentiment_score": "0.085592",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Shrugs Off Inflation Numbers; Exxon Shares Sink On Deal News",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-shrugs-off-inflation-numbers-exxon-shares-sink-on-deal-news/",
            "time_published": "20231011T150500",
            "authors": [
                "Investor's Business Daily",
                "KIMBERLEY KOENIG"
            ],
            "summary": "Stock Market Shrugs Off Inflation Numbers. Exxon Shares Sink On ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Exxon-05-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.224936,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "-0.02308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.170475",
                    "ticker_sentiment_score": "0.266934",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.124963",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.170475",
                    "ticker_sentiment_score": "0.057648",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.063943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.039171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "-0.01351",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.349647",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.045651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TKR",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "-0.026795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.170475",
                    "ticker_sentiment_score": "-0.016892",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TTWO",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.344067",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Asian markets surge as European stocks show mixed performance",
            "url": "https://cointelegraph.com/news/asia-eu-market-review-10-11-2023",
            "time_published": "20231011T142725",
            "authors": [
                "Prashant Jha"
            ],
            "summary": "Asian stocks surged across the board on Wednesday led by South Korean market while European markets had a mixed day.",
            "banner_image": "https://s3.cointelegraph.com/uploads/2023-10/b4d8e172-9320-482b-96c3-eea842b19c91.png",
            "source": "Cointelegraph",
            "category_within_source": "n/a",
            "source_domain": "cointelegraph.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.132123,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.131758",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "-0.236622",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PPRUF",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.061285",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Kidney Dialysis Provider Stocks Today? - Novo Nordisk  ( NYSE:NVO ) , DaVita  ( NYSE:DVA ) ",
            "url": "https://www.benzinga.com/news/large-cap/23/10/35190991/whats-going-on-with-kidney-dialysis-provider-stocks-today",
            "time_published": "20231011T135258",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "DaVita Inc DVA, Fresenius Medical Care AG FMS, and Baxter International Inc BAX shares fell sharply in reaction to Novo Nordisk A/S's NVO stopping semaglutide kidney outcomes trial FLOW based on early signs of efficacy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/11/dva.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.028791,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.173793",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.187398",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.462395",
                    "ticker_sentiment_score": "-0.352277",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.039516",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.462395",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.462395",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.462395",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Pops After Hinting Weight-Loss Drug Also Treats Kidney Disease",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-pops-after-hinting-weight-loss-drug-treats-kidney-disease/",
            "time_published": "20231011T134100",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Pops After Hinting Weight-Loss Drug Also Treats Kidney ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-NovoNordisk-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": 0.158956,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "-0.123634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.532043",
                    "ticker_sentiment_score": "0.219943",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Is Moving a Bunch of Stocks Wednesday Morning",
            "url": "https://www.fool.com/investing/2023/10/11/ozempic-is-moving-a-bunch-of-stocks-wednesday-morn/",
            "time_published": "20231011T133737",
            "authors": [
                "Dan Caplinger"
            ],
            "summary": "Find out who the winners and losers are.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.236141,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.24847",
                    "ticker_sentiment_score": "0.440239",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.113953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.187705",
                    "ticker_sentiment_score": "0.132755",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.24847",
                    "ticker_sentiment_score": "0.164807",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.307731",
                    "ticker_sentiment_score": "0.23569",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Top Stories Wednesday, Oct 11: Google AI-Powered Chatbot's Ethical Concerns, MGM Hackers Waited For Days Before Issuing Financial Demands, Costco Accused Of Sharing Confidential Health Data With Facebook - Alibaba Gr Holding  ( NYSE:BABA ) , Baidu  ( NASDAQ:BIDU ) ",
            "url": "https://www.benzinga.com/news/23/10/35193325/google-ai-powered-chatbots-ethical-concerns-mgm-hackers-waited-for-days-before-issuing-financial-dem",
            "time_published": "20231011T133635",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Alphabet Inc GOOG GOOGL Google and Discord Inc have been hosting an exclusive chat for avid users of Bard, Google's AI-powered chatbot. Integrating Bard into core Google services like Gmail, Maps, Docs, and YouTube has not been without challenges.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/11/google_bard_0.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.101325,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.075924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.170275",
                    "ticker_sentiment_score": "-0.099456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.21193",
                    "ticker_sentiment_score": "0.165375",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.137813",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.066655",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "-0.005985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIDU",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.075924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QUBSF",
                    "relevance_score": "0.042876",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.056461",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MGM",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "-0.079011",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "-0.057173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.197731",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TPST",
                    "relevance_score": "0.170275",
                    "ticker_sentiment_score": "0.052111",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.087249",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Up on Positive Kidney Outcomes Study Update",
            "url": "https://www.zacks.com/stock/news/2164364/novo-nordisk-nvo-up-on-positive-kidney-outcomes-study-update",
            "time_published": "20231011T132400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990678"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.090839,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CORT",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.211286",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.176385",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANVS",
                    "relevance_score": "0.319725",
                    "ticker_sentiment_score": "0.044498",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.087693",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks making the biggest moves premarket: Plug Power, Exxon Mobil, Pioneer, Novo Nordisk and more",
            "url": "https://www.cnbc.com/2023/10/11/stocks-making-the-biggest-moves-premarket-plug-power-exxon-mobil-pioneer-novo-nordisk-and-more.html",
            "time_published": "20231011T120054",
            "authors": [
                "Brian Evans"
            ],
            "summary": "These are the stocks posting the largest moves in premarket trading.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107142842-1666989609246-gettyimages-1437346799-mt_23542_ca2ead36-e2c5-4fe4-bc6d-f5e5ca97bd4d.jpeg?v=1697025654&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Market Insider",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.235939,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HUM",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.169262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SHW",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "-0.019958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "-0.217482",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.221576",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.328332",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TKR",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "-0.217482",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PLUG",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.112096",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.124179",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.223071",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TTWO",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.324375",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What's Going On With Novo Nordisk  ( NVO )  Stock Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35185290/novo-nordisk-stops-semaglutide-kidney-outcome-trial-based-on-early-signs-of-efficacy",
            "time_published": "20231011T114815",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has decided to stop the kidney outcomes trial FLOW based on a recommendation from the independent Data Monitoring Committee ( DMC ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/11/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.016781,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.657566",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.150592",
                    "ticker_sentiment_score": "0.224322",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nasdaq, S&P 500 Set To Open Higher Today: What's Moving Stock Futures? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Novo Nordisk  ( NYSE:NVO ) , SPDR S&P 500  ( ARCA:SPY ) , DaVita  ( NYSE:DVA ) ",
            "url": "https://www.benzinga.com/markets/equities/23/10/35189363/nasdaq-s-p-500-set-to-open-higher-ahead-of-fomc-minutes-producer-price-inflation-data-why-this-a",
            "time_published": "20231011T114129",
            "authors": [
                "Shanthi Rexaline"
            ],
            "summary": "Stock futures traded higher on Wednesday as buying momentum gradually builds amid hopes that the Federal Reserve may announce a pause at the month-end's rate-setting meeting. Futures sustained these gains, even in light of Fed Governor Michelle Bowman suggesting that more rate hikes may be ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Nasdaq_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.117591,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.046633",
                    "ticker_sentiment_score": "0.218467",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.093108",
                    "ticker_sentiment_score": "0.142229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "0.006286",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2023/10/11/is-novo-nordisk-stock-a-buy-now/",
            "time_published": "20231011T113700",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Ozempic and Wegovy are changing the weight-loss game.",
            "banner_image": "https://media.ycharts.com/charts/470463773989e4519efc13dd11f7ba02.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.795202"
                }
            ],
            "overall_sentiment_score": 0.28037,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.396798",
                    "ticker_sentiment_score": "0.39209",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "-0.05799",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New Strong Sell Stocks for October 11th",
            "url": "https://www.zacks.com/stock/news/2164087/new-strong-sell-stocks-for-october-11th",
            "time_published": "20231011T111200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "NVO, MT and PRPL have been added to the Zacks Rank #5 (Strong Sell) List on October 11, 2023.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.137087,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "-0.215687",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PRPL",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "-0.205512",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "LVMH shares fall to 2023 low as growth slows, pulling luxury sector down",
            "url": "https://www.cnbc.com/2023/10/11/lvmh-falls-to-2023-low-as-growth-slows-pulling-luxury-sector-lower.html",
            "time_published": "20231011T110651",
            "authors": [
                "Jenni Reid"
            ],
            "summary": "The world's largest luxury firm, seen as a bellweather for the industry, posted nine-month and third quarter results.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107242742-1684339552943-gettyimages-152327153-94174688RB_Chicago2507.jpeg?v=1684411201&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.174241,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CHDRF",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.044609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "0.043192",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PPRUF",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.044609",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is iShares International Equity Factor ETF  ( INTF )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2164076/is-ishares-international-equity-factor-etf-intf-a-strong-etf-right-now",
            "time_published": "20231011T102005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.217952,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "0.084991",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "-0.022023",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "-0.022023",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.117486",
                    "ticker_sentiment_score": "-0.025327",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Shares of dialysis providers drop after Ozempic's early kidney trial success",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/shares-dialysis-providers-drop-after-ozempics-early-kidney-trial-success-2023-10-11/",
            "time_published": "20231011T100200",
            "authors": [
                "Reuters"
            ],
            "summary": "The outdoor sign seen at the DaVita Dialysis clinic in Denver February 16, 2016. REUTERS/Rick Wilking/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/AHBNO2BUBNPCFNATO6JAAGGM5M.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.065527,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAX",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "-0.047442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "-0.088095",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.532941",
                    "ticker_sentiment_score": "-0.020546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.532941",
                    "ticker_sentiment_score": "0.112009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "0.095162",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Exciting Biotech Stocks to Buy With Less Than $10",
            "url": "https://www.fool.com/investing/2023/10/11/2-exciting-biotech-stocks-to-buy-with-less-than-10/",
            "time_published": "20231011T100000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "You can pick up these stocks for a song right now.",
            "banner_image": "https://media.ycharts.com/charts/b69f788ca1d2867dd7b043c913f9a358.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.27343,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CRBU",
                    "relevance_score": "0.142847",
                    "ticker_sentiment_score": "0.200807",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.261292",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.047844",
                    "ticker_sentiment_score": "0.079035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.281153",
                    "ticker_sentiment_score": "0.227989",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "European stocks edge up as Novo Nordisk offsets luxury sector jitters",
            "url": "https://www.reuters.com/markets/europe/luxury-stocks-drag-european-shares-lower-lvmh-disappointment-2023-10-11/",
            "time_published": "20231011T095400",
            "authors": [
                "Sruthi Shankar"
            ],
            "summary": "The logo of LVMH is seen at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, June 15, 2023. REUTERS/Gonzalo Fuentes/File photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZIWJEGPUJBJJNPJYWAZU6YAGFA.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.126632,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.302191",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FHI",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.005284",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167904",
                    "ticker_sentiment_score": "0.248106",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PPRUF",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.041125",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk shares rise, Silk Road Medical stock slumps and other movers",
            "url": "https://www.marketwatch.com/story/novo-nordisk-shares-rise-silk-road-medical-stock-slumps-and-other-movers-51165ebb",
            "time_published": "20231011T095000",
            "authors": [
                "MarketWatch"
            ],
            "summary": "Novo Nordisk, Thor Industries, Silk Road Medical, Fresenius Medical Care, and DaVita all showed stock price movement in pre-market trading ...",
            "banner_image": "https://images.mktw.net/im-866288/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.166995,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "THO",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.695658",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.028589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SILK",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "-0.100652",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.042937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.76367",
                    "ticker_sentiment_score": "0.166665",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "LVMH shares slump on sales miss, sending rival luxury-goods makers lower",
            "url": "https://www.marketwatch.com/story/lvmh-shares-slump-on-sales-miss-sending-rival-luxury-goods-makers-lower-daaaa0ef",
            "time_published": "20231011T092300",
            "authors": [
                "Louis Goss"
            ],
            "summary": "Shares in LVMH Moet Hennessy Louis Vuitton fell on Wednesday after the luxury goods seller posted underwhelming financial results that signaled the end of a post-pandemic boom in demand for Champagne and expensive handbags.",
            "banner_image": "https://images.mktw.net/im-866278/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.068856,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CHDRF",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.041581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.041581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HESAF",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.041581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.041581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.041581",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dialysis company shares plunge after Ozempic trial success vs. kidney trouble",
            "url": "https://www.marketwatch.com/story/dialysis-company-shares-plunge-after-ozempic-trial-success-vs-kidney-trouble-84c67de3",
            "time_published": "20231011T075900",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.",
            "banner_image": "https://images.mktw.net/im-654904/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.024052,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "-0.01837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "-0.011177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.010646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "-0.011177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "-0.012377",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today - Tesla  ( NASDAQ:TSLA ) , Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , Akero Therapeutics  ( NASDAQ:AKRO ) ",
            "url": "https://www.benzinga.com/markets/equities/23/10/35178000/wegovy-maker-novo-nordisk-akero-therapeutics-eli-lilly-athena-consumer-acquisition-tesla-why-the",
            "time_published": "20231011T015658",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. The Dow traded up 0.4% to 33,739.30 while the NASDAQ rose 0.58% to 13,562.84. The S&P 500 also rose, gaining 0.52% to 4,358.24.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Phongphan_on_Shutterstock_13.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.11519,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.301933",
                    "ticker_sentiment_score": "0.138261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "-0.117251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACCD",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "0.034115",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.050935",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk to stop Ozempic trial to treat renal impairment early",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-stop-ozempic-trial-treat-renal-impairment-early-2023-10-10/",
            "time_published": "20231010T213013",
            "authors": [
                "Reuters"
            ],
            "summary": "Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EJ4XVCXTRFPEZOEJML2CXR554M.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.08409,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.360752",
                    "ticker_sentiment_score": "0.158969",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Dow Jones Futures: Market Rally Hits Resistance; Tesla, Nvidia Lead New Buys",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-hits-resistance-tesla-nvidia-lead-new-buys/",
            "time_published": "20231010T210700",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Market Rally Hits Resistance. Tesla, Nvidia ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-Tesla-modelY-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.118479,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NTES",
                    "relevance_score": "0.130041",
                    "ticker_sentiment_score": "0.09941",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.256651",
                    "ticker_sentiment_score": "0.03544",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.287387",
                    "ticker_sentiment_score": "0.04906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.2255",
                    "ticker_sentiment_score": "0.02433",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.256651",
                    "ticker_sentiment_score": "0.027172",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.162145",
                    "ticker_sentiment_score": "0.056327",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.032646",
                    "ticker_sentiment_score": "-0.100797",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis",
            "url": "https://www.globenewswire.com/news-release/2023/10/10/2757941/0/en/Novo-Nordisk-will-stop-the-once-weekly-injectable-semaglutide-kidney-outcomes-trial-FLOW-based-on-interim-analysis.html",
            "time_published": "20231010T203700",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": -0.112238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.075161",
                    "ticker_sentiment_score": "0.038983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.075161",
                    "ticker_sentiment_score": "0.038983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.490988",
                    "ticker_sentiment_score": "-0.01595",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Oprah Winfrey Stock Aces New High After More Than Tripling",
            "url": "https://www.investors.com/news/ww-stock-soars-high-highsweight-loss-drug-play-oprah-winfrey-effect/",
            "time_published": "20231010T201800",
            "authors": [
                "APARNA NARAYANAN",
                "Investor's Business Daily"
            ],
            "summary": "WW Stock Soars To High. New Weight-Loss Drug Play Enjoys ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/BIZ04oprah101023ap.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.066486,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "-0.235462",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "WW",
                    "relevance_score": "0.491255",
                    "ticker_sentiment_score": "0.136312",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "0.051616",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "-0.235462",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Weight-Loss Drugs Aren't To Blame For The Snack Pullback. Pepsi Offers This Reason.",
            "url": "https://www.investors.com/news/weight-loss-drugs-blame-snack-pullback-pepsi-reason/",
            "time_published": "20231010T191900",
            "authors": [
                "Investor's Business Daily",
                "MIKE JUANG"
            ],
            "summary": "Weight-Loss Drugs Aren't To Blame For The Snack Pullback. Pepsi ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-pepsico-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.002395,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.069094",
                    "ticker_sentiment_score": "0.031013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.205225",
                    "ticker_sentiment_score": "-0.118387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.137671",
                    "ticker_sentiment_score": "-0.090393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.205225",
                    "ticker_sentiment_score": "0.16512",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.137671",
                    "ticker_sentiment_score": "-0.090393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.205225",
                    "ticker_sentiment_score": "0.16512",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.397098",
                    "ticker_sentiment_score": "-0.065275",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.205225",
                    "ticker_sentiment_score": "0.006449",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pepsi says people are skipping meals - and it's great for business",
            "url": "https://www.businessinsider.com/pepsi-says-people-skipping-meals-great-for-business-2023-10",
            "time_published": "20231010T190100",
            "authors": [
                "Dominick Reuter"
            ],
            "summary": "• PepsiCo says the impact of weight-loss drugs on its sales has so far been \"negligible.\" • Instead, the food and beverage giant is seeing \"meals becoming more mini-meals.\" • Analysts say companies will have plenty of time to prepare for the impact of weight-loss drugs.",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.148803,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.081564",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.211814",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Won't Stop Our Mindless Eating. The Food Selloff Doesn't Make Sense.",
            "url": "https://www.barrons.com/articles/ozempic-coke-pepsi-big-food-227b8597",
            "time_published": "20231010T175100",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "Ozempic Won't Kill Americans' Taste for Sugary Snacks ...",
            "banner_image": "https://images.barrons.com/im-51226844/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.421235,
            "overall_sentiment_label": "Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "KO",
                    "relevance_score": "0.651499",
                    "ticker_sentiment_score": "-0.599841",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.651499",
                    "ticker_sentiment_score": "-0.599841",
                    "ticker_sentiment_label": "Bearish"
                }
            ]
        },
        {
            "title": "US FDA warns online vendors to stop selling unapproved weight-loss drugs",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-online-vendors-stop-selling-unapproved-weight-loss-drugs-2023-10-10/",
            "time_published": "20231010T173400",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Oct 10 ( Reuters ) - The U.S.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/MWQBX4AG7VIENJLNKQYZCBNVSQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.103222,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "-0.199747",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "LVMH Q3 revenue rises 9%, slowing from post-pandemic frenzy",
            "url": "https://www.reuters.com/business/retail-consumer/lvmh-q3-revenue-rises-9-slowing-post-pandemic-frenzy-2023-10-10/",
            "time_published": "20231010T154900",
            "authors": [
                "Mimosa Spencer"
            ],
            "summary": "People walk past the Louis Vuitton store at Miami Design District, in Miami, Florida, U.S. November 30, 2021. REUTERS/Marco Bello Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/DQ6PH4MF6RJFJAPPJXN5PNE5GU.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.215203,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.340586",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company",
            "url": "https://www.cnbc.com/2023/10/10/ozempic-wegovy-novo-nordisk.html",
            "time_published": "20231010T150001",
            "authors": [
                "Natalie Rice"
            ],
            "summary": "Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history - thanks to its newfound success with two products: Ozempic and Wegovy. The drugs are once-weekly injectables of a medication called semaglutide, prescribed for Type 2 diabetes and weight loss.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107242742-1684339552943-gettyimages-152327153-94174688RB_Chicago2507.jpeg?v=1684411201&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.12464,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.30569",
                    "ticker_sentiment_score": "0.178328",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "-0.004395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Medication Insurance Coverage? Employers Embrace the Inclusion of Novo Nordisk's Wegovy in Health Coverage - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35157108/obesity-medication-insurance-coverage-employers-embrace-the-inclusion-of-novo-nordisks-wegovy-in-",
            "time_published": "20231010T120614",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Coverage for obesity medications, including Novo Nordisk A/S's NVO Wegovy, is expected to expand among U.S. employers, according to a new survey conducted by healthcare program provider Accolade Inc ACCD and research firm Savanta.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/10/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.24522,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AON",
                    "relevance_score": "0.280615",
                    "ticker_sentiment_score": "0.191788",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.280615",
                    "ticker_sentiment_score": "0.104575",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACCD",
                    "relevance_score": "0.410059",
                    "ticker_sentiment_score": "0.272484",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.410059",
                    "ticker_sentiment_score": "0.231083",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Still Buy the Nasdaq's Best-Performing September Stocks?",
            "url": "https://www.fool.com/investing/2023/10/10/should-you-still-buy-the-nasdaqs-best-performing-o/",
            "time_published": "20231010T105300",
            "authors": [
                "Jeremy Bowman"
            ],
            "summary": "Tech stocks sold off last month, but these three were gainers.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749789%2Fstock-market-chart.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999956"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.191799,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.10102",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.235254",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.112066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GFS",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.119139",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HZNP",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.145753",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Stock Drops Despite Market Gains: Important Facts to Note",
            "url": "https://www.zacks.com/stock/news/2162974/novo-nordisk-nvo-stock-drops-despite-market-gains-important-facts-to-note",
            "time_published": "20231009T215019",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the closing of the recent trading day, Novo Nordisk (NVO) stood at $92.06, denoting a -0.07% change from the preceding trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.217033,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.576289",
                    "ticker_sentiment_score": "0.398119",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "U.S. employers covering weight-loss drugs could nearly double in 2024 - survey",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-employers-covering-weight-loss-drugs-could-nearly-double-2024-survey-2023-10-09/",
            "time_published": "20231009T184400",
            "authors": [
                "Reuters"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. REUTERS/Victoria Klesty/Illustration//File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XCBP4P7UJVMCJILJNAO3DZ474Y.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.188135,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AON",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.180083",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.065112",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-Loss Drug Boom Has Another Ripple Effect - Rapid Growth Expected In Fill-Finish Market - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35142181/weight-loss-drug-boom-has-another-ripple-effect-rapid-growth-expected-in-fill-finish-market",
            "time_published": "20231009T152129",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Contract drug manufacturers are investing billions of dollars in expanding or constructing facilities that fill the injection pens used for weight-loss drugs like Novo Nordisk A/S's NVO Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/09/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.058462,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.108883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WXXWY",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "-0.097014",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.514619",
                    "ticker_sentiment_score": "0.32029",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.091076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.503288",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus",
            "url": "https://www.zacks.com/stock/news/2162451/beat-the-market-the-zacks-way-unitedhealth-novo-nordisk-check-point-software-in-focus",
            "time_published": "20231009T112000",
            "authors": [
                "Santanu Roy"
            ],
            "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                }
            ],
            "overall_sentiment_score": 0.14879,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LINC",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.025021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SOVO",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.117456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTU",
                    "relevance_score": "0.088799",
                    "ticker_sentiment_score": "0.109614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHKP",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.105999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.023008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FN",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.128",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HURN",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.153806",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.094033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.094033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.023008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QTRX",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.153806",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/10/09/2756588/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231009T111400",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 09 October 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Experts Weigh In On Ozempic's Evolving Side Effects And How To Handle Them - Novo Nordisk  ( OTC:NONOF ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35141499/experts-weigh-in-on-ozempics-evolving-side-effects-and-how-to-handle-them",
            "time_published": "20231009T094330",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "New side effects of the 'miracle' weight loss drug Ozempic are emerging, causing concern among patients and healthcare professionals alike. As reported by Salon, Ozempic, commonly used for weight loss and diabetes management, is coming under scrutiny for potential long-term side effects such as ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Ozempic,Insulin,Injection,Pen,Or,Insulin,Cartridge,Pen,For,Diabetics._9.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.070349,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "-0.134635",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Europe's Luxury stocks at risk of going out of style",
            "url": "https://www.reuters.com/markets/europe/europes-luxury-stocks-risk-going-out-style-2023-10-09/",
            "time_published": "20231009T051113",
            "authors": [
                "Lucy Raitano",
                "Mimosa Spencer"
            ],
            "summary": "A model presents a creation by designer Nicolas Ghesquiere as part of his Spring/Summer 2024 Women's ready-to-wear collection show for fashion house Louis Vuitton during Paris Fashion Week in Paris, France, October 2, 2023. REUTERS/Stephanie Lecocq/File photo Acquire Licensing Rights",
            "banner_image": "https://graphics.reuters.com/EUROPE-LUXURY/myvmgxmnmvr/chart.png",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.111324,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.043063",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.043063",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.051024",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Dividend Stock Just Got Hit With a Short Report. Is Now a Buying Opportunity?",
            "url": "https://www.fool.com/investing/2023/10/08/this-dividend-stock-just-got-hit-with-a-short-repo/",
            "time_published": "20231008T114500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Coca-Cola is the latest subject of the Bear Cave, an online publisher of reports on stock to sell short.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749343%2Fgettyimages-1135420212.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.067672,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.059415",
                    "ticker_sentiment_score": "0.033065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.089019",
                    "ticker_sentiment_score": "-0.007551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029728",
                    "ticker_sentiment_score": "-0.087974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.497657",
                    "ticker_sentiment_score": "0.177699",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.029728",
                    "ticker_sentiment_score": "-0.031027",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.089019",
                    "ticker_sentiment_score": "0.022185",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Popular weight loss drugs linked to higher risk of serious gastrointestinal problems",
            "url": "https://theweek.com/health/popular-weight-loss-drugs-linked-to-higher-risk-of-serious-gastrointestinal-problems",
            "time_published": "20231007T142215",
            "authors": [
                "Theara Coleman"
            ],
            "summary": "Study shows weight loss drugs have a higher risk of rare, but serious side effects The Week ...",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/x6gkWnBJifA6ENNARAUheR-415-80.jpg",
            "source": "The Week News",
            "category_within_source": "n/a",
            "source_domain": "theweek.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.048409,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "-0.099741",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRNWF",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "0.058449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "-0.032852",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049939",
                    "ticker_sentiment_score": "0.086815",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 No-Brainer Growth Stocks to Buy in October",
            "url": "https://www.fool.com/investing/2023/10/07/3-no-brainer-growth-stocks-to-buy-in-october/",
            "time_published": "20231007T105300",
            "authors": [
                "David Jagielski",
                "and Prosper Junior Bakiny",
                "Keith Speights"
            ],
            "summary": "The time is right to invest in these great stocks.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.996718"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.274002,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "0.217617",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.156207",
                    "ticker_sentiment_score": "0.168497",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "0.307637",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Shutdown Averted, Treasury Yields Flirt With 5%, Strong Payrolls Add to Fed Tightening Risk: The Week In The Markets - BlackRock  ( NYSE:BLK ) , Alphabet  ( NASDAQ:GOOGL ) , Citigroup  ( NYSE:C ) , PNC Finl Servs Gr  ( NYSE:PNC ) ",
            "url": "https://www.benzinga.com/markets/equities/23/10/35132440/shutdown-averted-treasury-yields-flirt-with-5-strong-payrolls-add-to-fed-tightening-risk-the-wee",
            "time_published": "20231006T201449",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "A week filled with significant events impacting the markets culminated in an unexpectedly strong September jobs report. Government Shutdown Averted. House Ousts McCarthy: The U.S. Congress managed to avoid a dramatic government shutdown just hours before the midnight deadline Oct. 1 by passing a ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Wall_Street_subway_sign_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.993856"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.185601,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PNC",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.013809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.048327",
                    "ticker_sentiment_score": "0.161895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DPZ",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "0.154064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "INFY",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "0.154064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "0.154064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "0.154064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.013809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "USEG",
                    "relevance_score": "0.048327",
                    "ticker_sentiment_score": "0.160857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NEE",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "0.154064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DMPZF",
                    "relevance_score": "0.048327",
                    "ticker_sentiment_score": "-0.036489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "0.201446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "-0.029978",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PGR",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FAST",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.038825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "0.201446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "-0.013809",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise - Molson Coors Beverage  ( NYSE:TAP ) , Coca-Cola  ( NYSE:KO ) , Novo Nordisk  ( NYSE:NVO ) , WK Kellogg  ( NYSE:KLG ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35132150/snacks-in-the-ozempic-era-food-beverage-stocks-crash-with-weight-loss-drugs-on-the-",
            "time_published": "20231006T200138",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Stocks in the food and beverage industry experienced their most challenging week since May 2022, further extending the declines seen in the preceding weeks. The First Trust Nasdaq Food & Beverage ETF FTXG plummeted by over 5% this week, marking its third consecutive week of losses and the ninth ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/snacks.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": -0.126327,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAP",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.021497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.051214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "-0.008491",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BF-A",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAG",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "K",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "-0.165273",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "HSY",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPB",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDP",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.103082",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STZ",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.067274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UTZ",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRBR",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "-0.159026",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "-0.183403",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Dow Jones Vaults 400 Points, Led By Disney Stock; Nasdaq 100 Movers Include Zscaler, CrowdStrike",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-vaults-400-points-disney-stock-nasdaq-100-movers-zscaler-crowdstrike/",
            "time_published": "20231006T193200",
            "authors": [
                "KEN SHREVE",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Vaults 400 Points, Led By Disney Stock. Nasdaq 100 ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999921"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.239795,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.306618",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.306618",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.269434",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.151306",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HON",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.166409",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.166409",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MANH",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.071483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.166409",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PDD",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.296174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.166409",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.213681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.206178",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CDNS",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.144204",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYBR",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.269434",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRT",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.238072",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.269434",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.112008",
                    "ticker_sentiment_score": "0.269434",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.206178",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": " ( NVO )  - Analyzing Novo Nordisk's Short Interest - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/short-sellers/23/10/35131592/nvo-analyzing-novo-nordisks-short-interest",
            "time_published": "20231006T191531",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk's NVO short percent of float has risen 45.45% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 0.16% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.267332,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.155473",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "12 Picks to Play the Future of Healthcare, From Our Roundtable Experts",
            "url": "https://www.barrons.com/articles/healthcare-stock-picks-roundtable-weight-loss-medicine-65441be4",
            "time_published": "20231006T180600",
            "authors": [
                "Lauren R. Rublin"
            ],
            "summary": "12 Picks to Play the Future of Healthcare, From Our Roundtable ... ...",
            "banner_image": "https://images.barrons.com/im-61306857/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.254405,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.148494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.316846",
                    "ticker_sentiment_score": "0.246201",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "These IBD 50 Companies Set To Report Blowout Earnings Growth Of Up To 320%",
            "url": "https://www.investors.com/stock-lists/ibd-50/growth-stocks-in-the-ibd-50-set-to-report-blowout-earnings-growth-of-up-to-320/",
            "time_published": "20231006T151400",
            "authors": [
                "Investor's Business Daily",
                "VIDYA RAMAKRISHNAN"
            ],
            "summary": "These IBD 50 Companies Set To Report Blowout Earnings Growth ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/08/Stock-Meta-zuckerberg-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.196789,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.190167",
                    "ticker_sentiment_score": "0.02906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IBKR",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.047573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOD",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.092994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "-0.092944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.103737",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.103737",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNPS",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.223661",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CDNS",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.140811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.103737",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APOS",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.040134",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DUOL",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.279301",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Top Stories Friday, Oct 6: Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger, Novo Nordisk's Weight Loss Drugs May Pose Serious Stomach Risks, Netflix's Local Content and Pricing Woes Undermine Growth in India: Today's Top Stories - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/news/23/10/35126486/regulatory-shadow-over-saudi-golf-league-liv-and-pga-tour-merger-novo-nordisks-weight-loss-drugs-may",
            "time_published": "20231006T140525",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The merger between the PGA Tour and Saudi-backed LIV Golf, initially set to be finalized by December 31, faces potential delays amid regulatory concerns in the U.S. and demands by PGA Tour players for a stake.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/golf.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.106716,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "-0.120588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "-0.131003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.16144",
                    "ticker_sentiment_score": "-0.00573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.100025",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "-0.082806",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAG",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "-0.067156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MU",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLN",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "0.044999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNAP",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "-0.11926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYDAF",
                    "relevance_score": "0.040622",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.100025",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MGM",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "-0.164297",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "-0.146916",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "-0.146916",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ATVI",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.121445",
                    "ticker_sentiment_score": "-0.011663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.081138",
                    "ticker_sentiment_score": "0.006186",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ON",
                    "relevance_score": "0.040622",
                    "ticker_sentiment_score": "-0.140577",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Growth Stock: Novo Nordisk vs. Pfizer",
            "url": "https://www.fool.com/investing/2023/10/06/better-growth-stock-novo-nordisk-vs-pfizer/",
            "time_published": "20231006T134500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Which of these two pharmaceutical giants should you add to your portfolio?",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.292247,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.368773",
                    "ticker_sentiment_score": "0.342819",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.477827",
                    "ticker_sentiment_score": "0.373981",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Weight Loss Drugs Like Wegovy, Ozempic May Pose Serious Stomach Risks, Study Suggests - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35123873/novo-nordisks-weight-loss-drugs-like-wegovy-ozempic-may-pose-serious-stomach-risks-study-suggests",
            "time_published": "20231006T130326",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A recent study published in JAMA has raised concerns about the potential risks associated with popular weight loss and diabetes drugs like Novo Nordisk A/S's NVO, Wegovy ( semaglutide ) , Ozempic ( semaglutide ) , and Saxenda ( liraglutide ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.175198,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.441059",
                    "ticker_sentiment_score": "-0.062406",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Structure Therapeutics  ( GPCR )  Stock Up 9% This Week: Here's Why",
            "url": "https://www.zacks.com/stock/news/2161548/structure-therapeutics-gpcr-stock-up-9-this-week-heres-why",
            "time_published": "20231006T124500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.107026,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.064498",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANIK",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.081787",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.374312",
                    "ticker_sentiment_score": "0.201286",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.213236",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not",
            "url": "https://www.fool.com/investing/2023/10/06/2-reasons-eli-lillys-mounjaro-might-beat-ozempic/",
            "time_published": "20231006T121500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Eli Lilly's drug looks better on paper, but Ozempic was on the market first.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.211302,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "0.158832",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.226477",
                    "ticker_sentiment_score": "0.157269",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "StockNews.com Initiates Coverage on Novo Nordisk A/S with Strong-Buy Rating",
            "url": "https://www.claytoncountyregister.com/news2/novo-nordisk-a-s-nysenvo-receives-new-coverage-from-analysts-at-stocknews-com-2/543742/",
            "time_published": "20231006T120715",
            "authors": [
                "Karl-W. Huelsenbeck"
            ],
            "summary": "StockNews.com Initiates Coverage on Novo Nordisk A/S with Strong ... Clayton County Register ...",
            "banner_image": "https://www.claytoncountyregister.com/wp-content/uploads/2023/07/mfrack_realistic_cinema_photo_of_stock_exchange_floor_7064d79d-9d72-4d43-9493-e7cfb6d33e1f.jpeg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.claytoncountyregister.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.307236,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.185414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ENV",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.185414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.185414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.870696",
                    "ticker_sentiment_score": "0.504252",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "ConAgra's Snack Revolution - Portion Sizes May Get A Makeover Amid Diet Drug Wave: Report - Conagra Brands  ( NYSE:CAG ) ",
            "url": "https://www.benzinga.com/markets/equities/23/10/35123304/conagras-snack-revolution-portion-sizes-may-get-a-makeover-amid-diet-drug-wave-report",
            "time_published": "20231006T115719",
            "authors": [
                "Nabaparna Bhattacharya"
            ],
            "summary": "ConAgra Brands, Inc. CAG could reportedly revamp the portion sizes of its snacks should the rising tide of weight-loss drug usage shake up the culinary consumption landscape. Conagra's scientists are investigating consumer behavior trends for likely modifications, Reuters reported, citing CEO ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/cag_1.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.004732,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CAG",
                    "relevance_score": "0.431065",
                    "ticker_sentiment_score": "-0.1213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.128902",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Makers of Ozempic, Mounjaro race to ramp up supply amid skyrocketing demand for drugs for weight loss",
            "url": "https://www.cnn.com/2023/10/06/health/ozempic-mounjaro-supply/index.html",
            "time_published": "20231006T102700",
            "authors": [
                "Meg Tirrell"
            ],
            "summary": "At Dr. Louis Aronne's weight loss center in New York City, the reactions to new medicines like Wegovy and Mounjaro can be extreme. \"People describe it as 'It's like a miracle,' like 'This has transformed my life,' \" said Aronne, director of the Center for Weight Management and Metabolic Clinical ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231005092450-weight-loss-drugs-stomach-side-effects.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.0144,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.151922",
                    "ticker_sentiment_score": "-0.002629",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.121804",
                    "ticker_sentiment_score": "0.002357",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Insulet Stock Traded Lower - Insulet  ( NASDAQ:PODD ) ",
            "url": "https://www.benzinga.com/news/23/10/35116325/why-insulet-stock-traded-lower",
            "time_published": "20231005T202206",
            "authors": [
                "Ryan Gustafson"
            ],
            "summary": "Insulet Corporation PODD shares traded lower Thursday. The stock has been under pressure this year amid the popularity of weight loss drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/05/diabetes-528678_1280.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.142696,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.382925",
                    "ticker_sentiment_score": "0.047891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.919882",
                    "ticker_sentiment_score": "0.309109",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.382925",
                    "ticker_sentiment_score": "0.047891",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy class has higher GI side effect risk than older weight loss drug in study",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-class-has-higher-gi-side-effect-risk-than-older-weight-loss-drug-study-2023-10-05/",
            "time_published": "20231005T183100",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "[1/3] A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/KHEPJRGLHFPO3FAOC545DSO7ZQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.119068,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "-0.243252",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Researchers link popular weight loss drugs to serious digestive problems for 'hundreds of thousands' worldwide",
            "url": "https://www.cnn.com/2023/10/05/health/weight-loss-drugs-serious-digestive-problems-study/index.html",
            "time_published": "20231005T173200",
            "authors": [
                "Brenda Goodman"
            ],
            "summary": "A new study suggests people taking popular injected medications for weight loss, including Wegovy, Ozempic, Saxenda and Victoza, may be at higher risk for serious digestive problems such as stomach paralysis, pancreatitis, and bowel obstructions, compared with those taking other types of weight ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230928082800-ozempic-injectable-drug-file.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.097948,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.085553",
                    "ticker_sentiment_score": "-0.048006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.021427",
                    "ticker_sentiment_score": "0.1954",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.021427",
                    "ticker_sentiment_score": "-0.001793",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biggest Oil Drop In A Year On Biden Security Plan, Magnificent 7 Stocks Do Not Like The New Data - Walmart  ( NYSE:WMT ) ",
            "url": "https://www.benzinga.com/markets/23/10/35111357/biggest-oil-drop-in-a-year-on-biden-security-plan-magnificent-7-stocks-do-not-like-the-new-data",
            "time_published": "20231005T151532",
            "authors": [
                "The Arora Report"
            ],
            "summary": "To gain an edge, this is what you need to know today. Please click here for a chart of oil futures. The chart shows a big run up in oil. When oil crossed over $90, $100 oil became the consensus in the marketplace. As the chart shows, the $100 consensus caused a short squeeze.",
            "banner_image": "https://cdn.benzinga.com/files/maxim-hopman-fixlqxahcfk-unsplash_7_0.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.200532,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "-0.150908",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "-0.150908",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "-0.150908",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "0.218613",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "-0.150908",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "0.218613",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "0.075357",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "0.075357",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.035397",
                    "ticker_sentiment_score": "0.241279",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "0.075357",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here are 18 stocks I am watching in the market, including Clorox, Rivian and Airbnb",
            "url": "https://www.cnbc.com/2023/10/05/here-are-18-stocks-jim-cramer-is-watching-including-clorox-rivian-airbnb.html",
            "time_published": "20231005T140123",
            "authors": [
                "Jim Cramer"
            ],
            "summary": "Here are some of the tickers on Cramer's radar for Thursday, Oct. 5, taken directly from his reporter's notebook.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/106984350-1638556308191-bottles-of-clorox-bleach-on-store-shelves_t20_gLoQyN.jpg?v=1696514483&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": -0.063116,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CARR",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.235658",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MPC",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.096352",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WING",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.08183",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.08183",
                    "ticker_sentiment_score": "-0.1302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.108538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAKE",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.108538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.223261",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.057832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSCO",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.059846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLX",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.089037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ELAN",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.117652",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSX",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.057832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.108538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.117652",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "-0.057832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JACK",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stories Thursday, Oct 5: Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power - Buckle  ( NYSE:BKE ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/news/23/10/35109401/disney-slashes-ticket-prices-for-children-us-government-ceases-free-distribution-of-merck-covid-pill",
            "time_published": "20231005T140104",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The Walt Disney Company DIS has unveiled a new series of discounts for children visiting its iconic Disneyland and Disney World parks. This strategic move comes amidst a noticeable decline in attendance and hotel occupancy, a trend exacerbated by the inflationary pressures that have made ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/05/disney_world_resort_entrance_0.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.121448,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.065845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VFS",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.195941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.01708",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.259537",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAG",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "-0.121431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STZ",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "-0.015264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOV",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BKE",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "-0.167724",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CLX",
                    "relevance_score": "0.102595",
                    "ticker_sentiment_score": "-0.073141",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.285825",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DIS",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.062025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy Success Uplifts Denmark's Economy And Reputation, But With Caution - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35103714/novo-nordisks-wegovy-success-uplifts-denmarks-economy-and-reputation-but-with-caution",
            "time_published": "20231005T130145",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S's NVO remarkable success with its weight-loss treatment, Wegovy, is not only a cause for celebration but also a source of caution for Denmark.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/05/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.3931,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.522333",
                    "ticker_sentiment_score": "0.531355",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.140896",
                    "ticker_sentiment_score": "0.010482",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Dividend Stocks That Turned $25,000 into $100,000 in 10 Years -- and None of Them Is a Tech Stock",
            "url": "https://www.fool.com/investing/2023/10/05/3-dividend-stocks-that-turned-25000-into-100000-in/",
            "time_published": "20231005T114500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "These stocks may not be done rising in value just yet.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.803643"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                }
            ],
            "overall_sentiment_score": 0.356355,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MA",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "0.291187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.204936",
                    "ticker_sentiment_score": "0.444006",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.370848",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease",
            "url": "https://www.globenewswire.com/news-release/2023/10/05/2755164/0/en/Phase-III-studies-to-investigate-survodutide-for-people-living-with-obesity-and-overweight-with-and-without-diabetes-cardiovascular-disease-and-chronic-kidney-disease.html",
            "time_published": "20231005T095300",
            "authors": [
                "Zealand Pharma"
            ],
            "summary": "Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease • SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide ( BI 456906 ) in people living with obesity and ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/8e5dac9c-86c4-4996-bce9-0f8ba208f970",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.026403,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HLF",
                    "relevance_score": "0.027164",
                    "ticker_sentiment_score": "0.05734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.027164",
                    "ticker_sentiment_score": "0.05734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.027164",
                    "ticker_sentiment_score": "0.05734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZLDPF",
                    "relevance_score": "0.054297",
                    "ticker_sentiment_score": "0.086994",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's the Best Big Pharma Stock of the Decade so Far  ( and It's Not Even Close ) ",
            "url": "https://www.fool.com/investing/2023/10/05/heres-the-best-big-pharma-stock-of-the-decade-so-f/",
            "time_published": "20231005T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "This stock puts the \"big\" in big pharma after massive gains in recent years.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.257867,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.391486",
                    "ticker_sentiment_score": "0.447177",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.116348",
                    "ticker_sentiment_score": "0.285979",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.230235",
                    "ticker_sentiment_score": "0.258954",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Walmart Reports 'Slight Pullback' In Food Demand As 'Miracle' Weight-Loss Drug Ozempic Gains Popularity - Novo Nordisk  ( NYSE:NVO ) , Walmart  ( NYSE:WMT ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35100939/walmart-reports-slight-pullback-in-food-demand-as-miracle-weight-loss-drug-ozempic-gains-populari",
            "time_published": "20231005T060450",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Walmart Inc. WMT indicates that there has been a decrease in shopping demand due to the use of appetite-suppressing medications such as Ozempic and Wegovy. According to a report by Bloomberg, Walmart, based in Bentonville, Arkansas, is analyzing changes in sales trends using anonymized shopper ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Walmart_Photo_by_Sundry_Photography_on_Shutterstock_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.125932,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SSTK",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.377691",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.605937",
                    "ticker_sentiment_score": "0.017447",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy bonanza looms large in Denmark",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-wegovy-bonanza-looms-large-denmark-2023-10-05/",
            "time_published": "20231005T050421",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "[1/2] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration//File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/OI5B73RMI5LO3NA6XLQGGU3ESM.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.266803,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CABGY",
                    "relevance_score": "0.043579",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMNR",
                    "relevance_score": "0.043579",
                    "ticker_sentiment_score": "0.135642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.087027",
                    "ticker_sentiment_score": "0.029316",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.043579",
                    "ticker_sentiment_score": "0.166489",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNSKF",
                    "relevance_score": "0.043579",
                    "ticker_sentiment_score": "-0.033671",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.256989",
                    "ticker_sentiment_score": "0.188318",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Medicare Price Talks to Include All 10 Drugmakers",
            "url": "https://www.kiplinger.com/retirement/medicare/medicare-price-talks-to-include-all-10-drugmakers",
            "time_published": "20231004T231326",
            "authors": [
                "Esther D&rsquo;Amico",
                "Joey Solitro"
            ],
            "summary": "The 10 pharmaceutical companies whose drugs will be part of the first cycle of the upcoming Medicare Drug Price Negotiation Program have agreed to participate in the talks, the White House announced on October 3. The drugmakers slated to take part in the discussions with Medicare are: AstraZeneca ...",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/SF4pYAF773BsTCSCwCrkMe-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.05959,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viatris makes progress on Ozempic patent challenge",
            "url": "https://www.marketwatch.com/story/viatris-makes-progress-on-ozempic-patent-challenge-990147ff",
            "time_published": "20231004T210500",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Board agrees to review patent covering certain strengths of blockbuster diabetes drug ...",
            "banner_image": "https://images.mktw.net/im-793547/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.24835,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "0.369204",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.782378",
                    "ticker_sentiment_score": "0.400994",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "2 Magnificent Growth Stocks to Buy Right Now",
            "url": "https://www.fool.com/investing/2023/10/04/2-magnificent-growth-stocks-to-buy-right-now/",
            "time_published": "20231004T132500",
            "authors": [
                "George Budwell"
            ],
            "summary": "These two biotech stocks could be big winners for patient investors.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749528%2Fgrowth-curve.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.26513,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.041001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.216141",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.041001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.041001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HRMY",
                    "relevance_score": "0.340915",
                    "ticker_sentiment_score": "0.334215",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Says Ginkgo Bioworks Stock Will Soar 132%, and Cathie Wood's Buying It. Should You?",
            "url": "https://www.fool.com/investing/2023/10/04/wall-street-says-ginkgo-bioworks-stock-will-soar/",
            "time_published": "20231004T130000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It's not a stock for the faint of heart, but its ambitious vision might pay off.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.217901,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "0.157051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.171688",
                    "ticker_sentiment_score": "0.158552",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "0.157051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "0.157051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Implied Volatility Surging for Novo Nordisk  ( NVO )  Stock Options",
            "url": "https://www.zacks.com/stock/news/2159883/implied-volatility-surging-for-novo-nordisk-nvo-stock-options",
            "time_published": "20231004T123800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors need to pay close attention to Novo Nordisk (NVO) stock based on the movements in the options market lately.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/2257.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.016814,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.560594",
                    "ticker_sentiment_score": "0.024016",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "PM360 Announces 2023 Trailblazer Award Winners",
            "url": "https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-winners-301943290.html",
            "time_published": "20231004T120000",
            "authors": [
                "PM360"
            ],
            "summary": "Top Companies, Marketers, CEOs, Products, and Initiatives Were Honored During Gala on October 3rd NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Last night at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 15th annual Trailblazer Awards.",
            "banner_image": "https://mma.prnewswire.com/media/545940/PM360_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.316548,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TVTX",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.337018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OPRX",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAYNF",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.082322",
                    "ticker_sentiment_score": "0.061158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NBIX",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.257102",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SYNH",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TARS",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CDNA",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "-0.068139",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRTX",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "-0.253155",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.305846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.041216",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HZNP",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "-0.292847",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SSUMF",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHRS",
                    "relevance_score": "0.041216",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.097016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.20635",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.020615",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35068559/drugmakers-agree-to-participate-for-medicare-drug-price-negotiation-with-biden-administration",
            "time_published": "20231003T173519",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration to halt the process.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.08438,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/10/35066601/obesity-drug-wegovys-triumph-to-catapult-novo-holdings-in-golden-era-of-wealth-boost",
            "time_published": "20231003T161710",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Holdings, the controlling shareholder of Novo Nordisk A/S NVO, is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.348145,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.667661",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "-0.134265",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drugmakers Agree To US Govt Price Talks Amid Pushback",
            "url": "https://www.barrons.com/news/drugmakers-agree-to-us-govt-price-talks-amid-pushback-c7eb4567",
            "time_published": "20231003T154800",
            "authors": [
                "Beiyi SEOW"
            ],
            "summary": "Drugmakers Agree To US Govt Price Talks Amid ...",
            "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP2007430630409481451714611589397832456678---1.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.048405,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "0.148076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "-0.235822",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.070725",
                    "ticker_sentiment_score": "-0.029698",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stories Tuesday, Oct 3: 'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals - Apple  ( NASDAQ:AAPL ) , ALX Oncology Holdings  ( NASDAQ:ALXO ) ",
            "url": "https://www.benzinga.com/news/23/10/35064552/airbnb-has-foundational-cracks-disney-follows-netflix-on-subscription-sharing-crackdown-microsofts-n",
            "time_published": "20231003T141120",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In a significant development, Microsoft Corp's MSFT CEO, Satya Nadella, has voiced concerns over the competitive landscape of content acquisition essential for training artificial intelligence ( AI ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/airbnbtoronto5.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.058194,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TGT",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.263048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.189076",
                    "ticker_sentiment_score": "0.273786",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.038162",
                    "ticker_sentiment_score": "0.139139",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.144617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.21709",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "-0.067693",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MU",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.143767",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "-0.017859",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "-0.098084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.14478",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "-0.038103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PNT",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.179376",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.067102",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.179376",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALXO",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "-0.146817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GME",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "-0.130984",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.021659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "-0.064201",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAK",
                    "relevance_score": "0.076236",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NXC",
                    "relevance_score": "0.038162",
                    "ticker_sentiment_score": "-0.036553",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Healthcare Stocks to Keep an Eye On",
            "url": "https://www.fool.com/investing/2023/10/03/3-healthcare-stocks-to-keep-an-eye-on/",
            "time_published": "20231003T134500",
            "authors": [
                "Jim Halley"
            ],
            "summary": "These three lesser-known healthcare companies have strong growth potential.",
            "banner_image": "https://media.ycharts.com/charts/708f4f4146d09672fb407e1bdf85ea69.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.17539,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.146304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TECH",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.222992",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.198384",
                    "ticker_sentiment_score": "0.165547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSUMF",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SOMMF",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.02641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.157705",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Anti-Obesity Drugs Are On The Come Up In A $44 Billion Market",
            "url": "https://www.forbes.com/sites/korihale/2023/10/03/anti-obesity-drugs-are-on-the-come-up-in-a-44-billion-market/",
            "time_published": "20231003T124807",
            "authors": [
                "Kori Hale"
            ],
            "summary": "Particularly, the Black community bears the brunt of this health crisis as 49% of adults in this demographic qualify as obese.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651c0d328c22c4372b6e3691/0x0.jpg?format=jpg&width=1200",
            "source": "Forbes",
            "category_within_source": "Money",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.002441,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.100429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "-0.032907",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drugmakers agree to negotiate prices in Medicare even as they sue to stop the program | Politics",
            "url": "https://www.cnn.com/2023/10/03/politics/drugmakers-medicare-price-negotiations/index.html",
            "time_published": "20231003T121200",
            "authors": [
                "Tami Luhby"
            ],
            "summary": "Drugmakers agree to negotiate prices in Medicare even as they sue to stop the program ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230929184725-medicare-drug-price-negotiations-092923.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.081676,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "0.056036",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.087547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "-0.014444",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare drug price negotiations move forward with all drugmakers participating, White House says",
            "url": "https://www.marketwatch.com/story/medicare-drug-price-negotiations-move-forward-with-all-drugmakers-participating-white-house-says-45b891dc",
            "time_published": "20231003T120000",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Novo Nordisk is latest drugmaker to challenge negotiation program in court.",
            "banner_image": "https://images.mktw.net/im-861558/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.026422,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.1789",
                    "ticker_sentiment_score": "-0.043857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "-0.012794",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.027305",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.018592",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet The Company Whose Hunger Suppressant Sent Shares Flying 505%",
            "url": "https://www.investors.com/news/technology/slno-stock-meet-soleno-the-company-whose-hunger-suppressant-sent-shares-skyrocketing/",
            "time_published": "20231003T120000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Meet The Company Whose Hunger Suppressant Sent Shares Flying ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/Stock-Drug-73-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.169373,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "0.13065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLNO",
                    "relevance_score": "0.385455",
                    "ticker_sentiment_score": "0.141436",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114409",
                    "ticker_sentiment_score": "0.127724",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk owner sees IPO window opening within 18 months",
            "url": "https://www.reuters.com/markets/deals/novo-holdings-ceo-says-ipo-window-open-within-18-months-2023-10-03/",
            "time_published": "20231003T102034",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little REFILE - CORRECTING LOCATION/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/OOPFLRIEIVNWTEX265XZS6DTNY.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.233926,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.390092",
                    "ticker_sentiment_score": "0.399341",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "European stocks steady as banks offset declines in utilities",
            "url": "https://www.reuters.com/markets/europe/european-stocks-remain-under-pressure-us-yields-stay-high-2023-10-03/",
            "time_published": "20231003T083400",
            "authors": [
                "Sruthi Shankar"
            ],
            "summary": "The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, September 29, 2023. REUTERS/Staff/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/5ZYQDXROBZJMBENNFMBY4ZDOGM.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": -0.004943,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "-0.004174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZLNDY",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.081395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VWSYF",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "-0.143279",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.170275",
                    "ticker_sentiment_score": "0.284066",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Outpaces Stock Market Gains: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2158876/novo-nordisk-nvo-outpaces-stock-market-gains-what-you-should-know",
            "time_published": "20231002T215016",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Novo Nordisk (NVO) closed at $91.80, marking a +0.95% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default120.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.161731,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.615462",
                    "ticker_sentiment_score": "0.29129",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-patent-office-wont-review-two-novo-nordisk-patents-wegovy-ozempic-2023-10-02/",
            "time_published": "20231002T205400",
            "authors": [
                "Blake Brittain"
            ],
            "summary": "US Patent Office won't review two Novo Nordisk patents for ...",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/e80269c0-8a61-4e5d-afa1-d2c4740ed247.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.158709,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.360752",
                    "ticker_sentiment_score": "0.312194",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.468029",
                    "ticker_sentiment_score": "-0.125002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Shares of Structure Therapeutics Are Up Monday",
            "url": "https://www.fool.com/investing/2023/10/02/why-shares-of-structure-therapeutics-are-up-monday/",
            "time_published": "20231002T194847",
            "authors": [
                "Jim Halley"
            ],
            "summary": "The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.29063,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.163951",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.337869",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JEF",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.145174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.163951",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/10/35035468/big-pharmas-weight-loss-drugs-vs-snacking-industry-who-will-prevail",
            "time_published": "20231002T194714",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The rising prevalence of obesity and diabetes drugs like Novo Nordisk A/S's NVO Wegovy and Ozempic is triggering concerns among investors about the future of the snacking industry. Despite this, J.M. Smucker's SJM CEO, Mark Smucker, remains optimistic about the future of iconic snack brands like ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/02/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.085662,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.03301",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.23992",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.23992",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "-0.132163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSY",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.249639",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TWNK",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.116621",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drugmakers opt in to Medicare drug price negotiations - here's what happens next",
            "url": "https://www.cnbc.com/2023/10/02/drugmakers-agree-to-medicare-price-negotiations-whats-next.html",
            "time_published": "20231002T193402",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/106330644-1578667127386rts2xt0x.jpg?v=1696275242&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.014398,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.183448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.2125",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.102231",
                    "ticker_sentiment_score": "-0.114146",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "-0.057993",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA approves Novo Nordisk's Rivfloza therapy for rare kidney condition",
            "url": "https://www.foxbusiness.com/healthcare/fda-approves-novo-nordisks-rivfloza-therapy-rare-kidney-condition",
            "time_published": "20231002T175546",
            "authors": [
                "Reuters"
            ],
            "summary": "Novo Nordisk said on Monday the U.S. Food and Drug Administration ( FDA ) had approved its therapy to treat a rare genetic condition that affects the kidneys.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/6b48616e-f7ac-4dcf-9a75-7a9b8d560f48/dc7a8a9a-504a-4a23-86df-05f9985338b1/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.080999,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.340915",
                    "ticker_sentiment_score": "0.434992",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Drugmakers sign on to negotiate Medicare prices under protest",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-sign-negotiate-medicare-prices-under-protest-2023-10-02/",
            "time_published": "20231002T171200",
            "authors": [
                "Michael Erman",
                "Patrick Wingrove"
            ],
            "summary": "U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan Ernst/File Photo Acquire Licensing Rights",
            "banner_image": "https://graphics.reuters.com/HEALTH-USA/gdvzwdbjjpw/chart.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.040332,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169081",
                    "ticker_sentiment_score": "-0.101087",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.033017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.033017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.033017",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This fund shows that industry expertise can help you make a lot of money in the stock market",
            "url": "https://www.marketwatch.com/story/this-fund-shows-that-industry-expertise-can-help-you-make-a-lot-of-money-in-the-stock-market-5d104b1d",
            "time_published": "20231002T162800",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "The managers of the Janus Henderson Global Life Sciences Fund have direct experience to help them separate promising innovators from flashes in the pan.",
            "banner_image": "https://images.mktw.net/im-861100?width=700&height=593",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.174392,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ETNB",
                    "relevance_score": "0.083107",
                    "ticker_sentiment_score": "-0.074703",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04161",
                    "ticker_sentiment_score": "0.084583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JHG",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.11181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.083107",
                    "ticker_sentiment_score": "0.089042",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.083107",
                    "ticker_sentiment_score": "-0.03668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.083107",
                    "ticker_sentiment_score": "-0.074703",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.083107",
                    "ticker_sentiment_score": "0.238236",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "US FDA approves Novo Nordisk's therapy for rare genetic condition",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-novo-nordisks-therapy-rare-genetic-condition-2023-10-02/",
            "time_published": "20231002T152919",
            "authors": [
                "Reuters"
            ],
            "summary": "A general view of the offices of Danish drugmaker Novo Nordisk in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File photo Acquire Licensing Rights Oct 2 ( Reuters ) - Novo Nordisk ( NOVOb.CO ) said on Monday the U.S.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4WLZLNQL4ZJEDKFVTSWJTGWOHA.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.199303,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.328803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bernard Arnault's lawyer dismisses allegations of money laundering as 'absurd' | Business",
            "url": "https://www.cnn.com/2023/10/02/business/arnault-sarsikov-money-laundering-allegations/index.html",
            "time_published": "20231002T131200",
            "authors": [
                "Chris Liakos",
                "Anna Cooban"
            ],
            "summary": "Bernard Arnault's lawyer dismisses allegations of money laundering as 'absurd' ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/221215140542-bernard-arnault.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.124002,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.274066",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.10562",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bernard Arnault's lawyer dismisses allegations of money laundering as 'absurd' | Business",
            "url": "https://edition.cnn.com/2023/10/02/business/arnault-sarsikov-money-laundering-allegations/index.html",
            "time_published": "20231002T131200",
            "authors": [
                "Chris Liakos",
                "Anna Cooban"
            ],
            "summary": "Bernard Arnault's lawyer dismisses allegations of money laundering as 'absurd' CNN International ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/221215140542-bernard-arnault.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "edition.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.124002,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.274066",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.10562",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day",
            "url": "https://www.zacks.com/stock/news/2158590/acm-research-and-advance-auto-parts-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
            "time_published": "20231002T122500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Chicago, IL - October 2, 2023 - Zacks Equity Research shares ACM Research ( ACMR Quick QuoteACMR - ) as the Bull of the Day and Advance Auto Parts ( AAP Quick QuoteAAP - ) as the Bear of the Day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cb/577.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.152207,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAP",
                    "relevance_score": "0.242027",
                    "ticker_sentiment_score": "-0.080033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.087631",
                    "ticker_sentiment_score": "0.027321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACMR",
                    "relevance_score": "0.225224",
                    "ticker_sentiment_score": "0.251365",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.01756",
                    "ticker_sentiment_score": "0.155341",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.139771",
                    "ticker_sentiment_score": "0.043998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.105064",
                    "ticker_sentiment_score": "0.040069",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/10/02/2752729/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231002T121100",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 02 October 2023 - On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        }
    ]
}